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ABSTRACT 
 
The mucosal membranes represent the most common portal of entry for human pathogens 
and are protected by a specialised mucosal immune system which is distinct from the 
systemic immune system.  Salmonella enterica serovar Typhi (S. Typhi) penetrates the body 
through the intestinal mucosa and causes both mucosal and systemic illness.  Mucosal 
vaccination against S. Typhi with the licensed live oral typhoid vaccine Ty21a should elicit 
protective cellular responses both systemically and at the mucosal surface.  However, 
nothing is known about the cell-mediated immune responses that are induced locally in the 
mucosa of the small intestine.  It is also unclear whether Ty21a can elicit cellular mucosal 
immune responses at other mucosal surfaces, a property that would make it a candidate 
vaccine vector.  This study aimed to answer these questions and to determine whether 
there is a correlation between the immune response elicited at different mucosal sites or 
between the intestinal mucosa and blood.   
Healthy adults were either vaccinated with Ty21a (n=10) or allocated to the unvaccinated 
control group (n=7).  Blood was collected from both groups on day 0 (pre-vaccination 
sample) and day 18 (post-vaccination sample) by venesection.  Cells were separated by 
differential centrifugation and analysed by flow cytometry.  Mucosal samples (duodenum ± 
sigmoid colon) were collected by endoscopy and mucosal pinch-biopsy on day 18.  Cells 
were separated by collagenase digestion and mechanical disruption and analysed by flow 
cytometry.  Two functional T cell assays, an intracellular cytokine staining assay (interferon-
γ, tumour necrosis factor-α and interleukin-2) and a lymphoproliferation assay, were used 
to assess antigen-specific cellular immune responses. 
The results demonstrated that in blood, there was no statistically significant difference in 
the mean percentage of antigen-specific CD4+ T cells in the intracellular cytokine staining 
assay between the control and vaccinated groups at day 0 but there was at day 18.  This 
was due to an unexpected fall in the mean percentage of antigen-specific CD4+ T cells in 
the control group between day 0 and day 18.  In the blood lymphoproliferation assay, there 
was no statistically significant difference between the control and vaccinated groups at day 
0 or day 18.  There was, however, a statistically significant increase in the mean percentage 
of antigen-specific cytokine-producing CD4+ T cells in the vaccinated group compared to 
the control group in duodenal tissue, but not in the colon at day 18.  In the vaccinated 
xvi 
 
group, there was not a strong correlation between duodenum and colon or between 
duodenum and blood in terms of the percentage of antigen-specific cytokine-producing 
CD4+ T cells.  
This is the first study to report antigen-specific mucosal T cell responses to an oral vaccine, 
and we were able to demonstrate a significant increase in intracellular cytokine responses 
to Ty21a antigens in T cells from the mucosal surface.  The results from this study support 
the theory that local immune responses against pathogens such as S. Typhi which gain 
access to the body through mucosal membranes are important.  In addition, they suggest 
that the cellular immune response measured in peripheral blood may not correlate with 
that measured at the mucosal surface, emphasising the potential value of obtaining 
mucosal tissue for direct study.  This has implications for the evaluation of future vaccine 
candidates which often relies on systemic immune responses to assess vaccine 
immunogenicity.  This study will now be extended beyond this interim analysis by recruiting 
more individuals to confirm the findings.  
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CHAPTER 1: INTRODUCTION AND LITERATURE REVIEW 
1.1 MUCOSAL IMMUNE SYSTEM 
Mucous membranes cover an area of several hundred square metres in an adult, lining the 
gastrointestinal, respiratory and urogenital tracts as well as the ducts of all the exocrine 
glands in the body.  The physiological functions of mucous membranes, for example gas 
exchange, food absorption and reproduction, require them to be thin and permeable and, 
consequently, they are the major portal of entry for human pathogens, especially bacteria 
and viruses (Murphy et al., 2008).  These mucosal membranes are protected by a highly 
specialised innate and adaptive mucosal immune system.  This local immune system 
contributes approximately 80% of all immunocytes in a healthy adult.  These immunocytes 
are found in the mucosa-associated lymphoid tissues (MALT), which together form the 
largest mammalian lymphoid organ system (Holmgren and Czerkinsky, 2005).   
1.1.1 Organisation of the mucosal immune system 
The mucosal immune system can be divided into inductive sites and effector sites (Figure 
1.1).  At inductive sites, antigens that have been sampled from the mucosal surface are 
presented to cognate naïve T and B cells in order to stimulate them to differentiate into 
effector cells.  At effector sites, these effector cells perform their effector functions after 
extravasation and differentiation (Brandtzaeg et al., 2008). 
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Figure 1.1 Schematic depiction of the mucosal immune system from (Brandtzaeg and 
Pabst, 2004).  Mucosal immune inductive sites are constituted by regional mucosa-
associated lymphoid tissue (MALT) such as Peyer’s patches and isolated lymphoid follicles.  
MALT has an M cell (M)-containing follicle-associated epithelium through which antigen 
can be transported to reach antigen-presenting cells (APCs) such as dendritic cells (DCs), 
macrophages and follicular dendritic cells (FDCs).  Exogenous antigens can also be captured 
by subepithelial DCs.  APCs migrate to local and regional lymph nodes where they prime 
naïve B and T cells to become memory-effector B and T cells.  These primed cells migrate 
into the peripheral blood and are transported to mucosal effector sites where 
extravasation occurs.  Extravasation is controlled by the endothelial cells.  The gut mucosal 
effector site, the lamina propria, contains IgA, IgM and IgG plasma cells and T lymphocytes.  
The IgA and IgM plasma cells produce secretory IgA (SIgA) and secretory IgM (SIgM), 
respectively, via polymeric Ig receptor (pIgR)-mediated epithelial transport. 
 
1.1.1.1 Immune inductive sites of mucosae 
Inductive sites consist of organised MALT and local and regional mucosa-draining lymph 
nodes.  MALT is sub-divided according to anatomical regions, for example gut-associated 
lymphoid tissue (GALT), bronchus-associated lymphoid tissue (BALT) and nasopharynx-
associated lymphoid tissue (NALT).  Mucosa-draining lymph nodes include the mesenteric 
lymph nodes (MLN) and the cervical lymph nodes (CLN).  The structure of all MALT 
resembles that of lymph nodes, with T cell zones, B cell follicles and antigen-presenting 
cells such as dendritic cells and macrophages.  In contrast to lymph nodes, MALT lacks 
afferent lymphatics because antigens are sampled directly from the mucosal surface 
(Brandtzaeg et al., 2008).  
 
GALT, the largest and best-defined MALT structure, includes Peyer’s patches, the appendix 
and isolated lymphoid follicles (ILFs).  Peyer’s patches contain between five and 200 
aggregated lymphoid follicles and in humans, are found mainly in the distal ileum 
(Brandtzaeg et al., 2008).  The number of macroscopically visible Peyer’s patches varies 
with age, increasing from around 50 before 30 weeks gestation to 100 at birth and 250 in 
the mid-teens before decreasing to approximately 100 over 70 years of age (Brandtzaeg et 
al., 2008; Cornes, 1965).  There are over 30,000 ILFs in the human gut.  In both the small 
and large intestine, ILFs increase in density distally (Brandtzaeg et al., 2008).  
 
Lymphocytes encounter antigens derived from the intestinal lumen in GALT and MLNs.  
GALT structures such as Peyer’s patches acquire antigens directly from the intestinal lumen 
in different ways.  Soluble protein antigens can be passively absorbed across the intestinal 
epithelium.  Alternatively, antigens can be acquired through a follicle-associated epithelium 
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containing specialised M cells (M for microvilli or microfold).  M cells overlie approximately 
10% of Peyer’s patches (Lefrancois and Puddington, 2006).  Antigens are transported 
through the apical membrane of the M cell and then through its extensively folded 
basement membrane, which is closely apposed to underlying antigen-presenting cells 
(APCs) and T cells (Murphy et al., 2008).  MLNs receive antigen or antigen-bearing APCs in 
afferent lymph from the intestine and efferent lymph drainage from Peyer’s patches 
(Lefrancois and Puddington, 2006). 
 
1.1.1.2 Effector sites of mucosae 
After activation in secondary lymphoid tissues, lymphocytes are able to leave the immune 
inductive sites and migrate to all non-lymphoid tissues (Lefrancois and Puddington, 2006).  
These effector sites include the lamina propria of various mucous membranes, the stroma 
of exocrine glands and surface epithelia (Brandtzaeg and Pabst, 2004).  The lamina propria 
of the intestine is defined as a ‘loosely organised connective tissue beneath the basement 
membrane supporting the overlying epithelial cells of the small and large intestine’ 
(Lefrancois and Puddington, 2006).  It contains cells of both the innate and adaptive 
immune system, including IgA-producing plasma cells, dendritic cells, macrophages and 
lymphocytes.  In the lung, effector cells are found in the lung parenchyma, which is 
analogous to the intestinal lamina propria, and the airways (Lefrancois and Puddington, 
2006). 
1.1.2 Compartmentalisation of immunity 
1.1.2.1 Mucosal versus systemic immunity 
The mucosal immune system is distinct from the systemic immune system.  The concept 
that mucosal humoral immunity is distinct from systemic humoral immunity was conceived 
by Besredka in 1919.  He orally immunised rabbits with Shigella dysenteriae and showed 
that they were protected against fatal dysentery, irrespective of their serum antibody titre.  
This implied that an adaptive immune response was generated in the gut that was 
independent of the systemic immune response (Brandtzaeg, 1996).  The distinctive 
features of the mucosal immune system are summarised in Table 1.1. 
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Anatomical features Intimate interactions between mucosal epithelia 
and lymphoid tissues 
Discrete compartments of diffuse lymphoid 
tissue and more organised structures such as 
Peyer’s patches, isolated lymphoid follicles and 
tonsils 
Specialised antigen-uptake mechanisms, e.g. M 
cells in Peyer’s patches, adenoids and tonsils 
Effector mechanisms Activated/memory T cells predominate even in 
the absence of infection 
Nonspecifically activated ‘natural’ 
effector/regulatory T cell present 
Immunoregulatory environment Active downregulation of immune responses 
(e.g. to food and other innocuous antigens) 
predominates 
Inhibitory macrophages and tolerance-inducing 
dendritic cells 
Table 1.1 Distinctive features of the mucosal immune system, from (Murphy et al., 2008). 
1.1.2.2 Compartmentalisation of the mucosal immune system 
The concept of a common mucosal immune system (MIS) whereby activation of 
immunocytes at one site could induce an immune response at remote mucosal effector 
sites has support (Czerkinsky et al., 1987; McDermott and Bienenstock, 1979; Mestecky et 
al., 1978).  For example, Mestecky et al. orally immunised humans with capsules which 
contained killed Streptococcus mutans and found specific antibodies in saliva and lacrimal 
secretions (Mestecky et al., 1978).  More recently, however, the concept of a common MIS 
has been superceded by that of a compartmentalised MIS, in which specific mucosal 
inductive sites are linked with particular effector sites (Eriksson et al., 1998; Haneberg et 
al., 1994; Kozlowski et al., 1997).  For example, Haneberg et al. immunised mice with 
cholera toxin via different routes (oral cavity, stomach, colon-rectum or vagina) and 
measured the specific IgA antibody response at these different sites.  They found that the 
concentration of specific IgA in secretions at the different mucosal sites varied greatly, 
depending on the route of immunisation (Haneberg et al., 1994).  Such 
compartmentalisation within the MIS restricts the choice of vaccination route for any given 
disease.  For example, giving an oral vaccine for a disease of the female genital tract would 
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not necessarily induce an optimally effective immune response in the female genital tract 
mucosa (Figure 1.2).   
 
 
 
Figure 1.2 Expression of mucosal IgA immune responses after different routes of 
vaccination, from (Holmgren and Czerkinsky, 2005).  Shading indicates the strength of the 
immune response. 
1.1.3 Mucosal vaccination  
Arguably the greatest advantage of mucosal vaccination over parenteral vaccination is that 
mucosal vaccination establishes humoral and cellular protective immune responses both 
systemically and at mucosal surfaces, whereas parenteral vaccination is only effective in 
clearing systemic infections and fails to protect at the mucosal surface (Mann et al., 2009).  
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Given that mucosal surfaces represent the most common portal of entry or colonisation for 
human pathogens, there is a clear advantage of a vaccination strategy that induces both 
layers of antigen-specific immunity (Mann et al., 2009).  In addition, mucosal vaccination 
targets immune inductive sites and protects against infection and disease, whereas 
parenteral vaccination does not target inductive sites and offers protection predominantly 
against disease (Medina and Guzman, 2001).  
The oral route of vaccination offers other significant advantages over systemic delivery.  
Whereas the injection of a vaccine with a needle and syringe requires medical 
professionals, oral vaccines are non-invasive and involve a relatively simple administration 
technique, offering the potential for self-administration.  This makes them more suitable 
for mass-vaccination campaigns (Baumann, 2008).  Furthermore, oral vaccines would 
remove the risk of injury or cross infection through contaminated needles.  Finally, mucosal 
vaccines have a much smaller impact on the environment; there are no needles and 
syringes which need to be decontaminated and disposed of (Mann et al., 2009). 
Successful oral vaccines include the live-attenuated polio vaccine (Oral Polio Vaccine®) and 
the live-attenuated monovalent human rotavirus vaccine (RotaRix®).  The Oral Polio 
Vaccine® (OPV) was developed by Albert Sabin in the 1960s and was the first approved 
mucosal vaccine (Yuki and Kiyono, 2009).  A global polio eradication campaign using OPV 
reduced the number of cases from an estimated 350,000 worldwide in 1988 to 2,971 
worldwide in 2000 (Chumakov et al., 2007).  The RotaRix® vaccine protects against 
rotavirus which is a major cause of acute gastroenteritis worldwide in children less than 
five years old.  Vaccine efficacy ranges from 41% to 92% depending on the serotype 
involved (Yuki and Kiyono, 2009). 
Live mucosal vaccines have obvious strengths but there are problems and potential hazards 
associated with them.  These include the possibility that they will revert to virulence and 
cause disease in recipients, or that they will develop new mutations.  The OPV, for 
example, has been associated with the development of paralytic poliomyelitis in vaccinees 
and their contacts.  The incidence of this vaccine-associated paralytic poliomyelitis is 
highest in immunosuppressed patients, suggesting that immunosuppression should be a 
contraindication for live mucosal vaccines (Ogra et al., 1980).  Other concerns include 
interference by microorganisms at the mucosal surface and, in young children, interference 
by pre-existing mucosal antibody passed on via breast-feeding (Ogra et al., 1980).  There is 
also the need for cold chain storage and distribution. 
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1.1.4 Cellular immunity 
T cell precursors are derived from pluripotent haematopoietic stem cells in the bone 
marrow.  They migrate through the blood to the thymus where further differentiation to 
mature naïve T cells occurs (Picker and Butcher, 1992).  Bone marrow and the thymus are 
both central lymphoid organs.  When T cell precursors first enter the thymus from the bone 
marrow, they are known as CD4-CD8- double-negative thymocytes, expressing neither of 
these T cell surface markers.  They then become CD4+CD8+ double-positive thymocytes.  
Double-positive thymocytes undergo positive selection, whereby cells that are potentially 
reactive to antigens presented by self-MHC molecules are selected for, and negative 
selection, whereby self-reactive T cells are eliminated.  Cells that do not receive T cell 
receptor (TCR) signals are also eliminated.  Double-positive thymocytes are then induced to 
differentiate into single-positive thymocytes before their eventual export from the thymus 
(Takahama, 2006). 
 
On leaving the thymus, naïve T cells enter the bloodstream.  When a peripheral lymphoid 
organ is reached, they leave the blood and migrate through the lymphoid tissue.  Entry into 
lymphoid tissue is a four-step process involving rolling, activation by chemokines, adhesion 
by integrins and diapedesis (Eksteen et al., 2008).  If naïve T cells do not encounter their 
cognate antigen, they return to the bloodstream via the lymphatic system and continue to 
re-circulate between blood and peripheral lymphoid tissues.  If a naïve T cell encounters its 
cognate antigen presented by an APC, T cell activation occurs.  Naïve CD8+ T cells recognise 
antigen presented by major histocompatibility complex (MHC) class I molecules on APCs 
whereas naïve CD4+ T cells recognise antigen presented by MHC class II molecules on APCs.  
Activation requires three signals (Jambo et al., 2010): 
1. Recognition of the foreign-peptide: self-MHC complex on APCs by the TCR on T 
cells and ligation of the co-receptor CD4 or CD8 
2. Interaction of co-stimulatory molecules on T cells (CD40L and CD28) with their 
receptors on APCs (CD40 and CD80/CD86, respectively) 
3. Secretion of polarising cytokines by APCs.  The particular cytokines secreted 
determine whether CD4+ T cells differentiate into effector T helper 1 (Th1), T 
helper 2 (Th2), T helper 17 (Th17) or regulatory T cells (Tregs) 
 
Upon activation, naïve T cells become antigen-specific effector T cells.  Naïve CD4+ T cells 
differentiate into Th1, Th2, Th17 or Treg cells.  These T cell subsets have different 
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functions.  Th1 cells secrete inflammatory cytokines such as interferon-γ (IFN-γ), tumour 
necrosis factor-α (TNF-α) and interleukin 2 (IL-2) which are necessary for the clearance of 
intracellular bacteria and viruses.  They mediate cellular immunity by activating 
macrophages and CD8+ effector cells.  Th2 cells secrete cytokines such as IL-4, IL-5 and IL-
13 and mediate immunity against parasitic infections.  They also play a role in allergic 
responses.  Th17 cells protect against extracellular bacterial infections and play a role in 
autoimmunity (MacLeod et al., 2009).  Tregs maintain peripheral tolerance (Vignali et al., 
2008) and they have suppressive properties, preventing a protective immune response 
becoming a destructive immunopathology (Thompson and Powrie, 2004).  Naïve CD8+ T 
cells become cytotoxic T lymphocytes (CTL) on activation.  CTLs release perforin and 
granzymes leading to the induction of apoptosis of target cells (Seder et al., 2008). 
 
Antigen-specific effector T cells that remain in the body during the contraction phase of an 
immune response become long-lived memory T cells (Woodland and Kohlmeier, 2009).  
Memory T cells can also be formed directly from the differentiation of naïve T cells, without 
first passing through an effector T cell phase (Moulton and Farber, 2006).  There are two 
types of memory cell, central memory T cells (Tcm) and effector memory T cells (Tem), 
which can be distinguished on the basis of their phenotypic and functional properties.  Tcm 
are CD62L+CCR7+ (as are naïve T cells) whereas Tem are CD62L-CCR7-.  Tcm preferentially 
localise to lymphoid tissues (as do naïve T cells) whereas Tem preferentially localise to 
peripheral tissues (Woodland and Kohlmeier, 2009).  In contrast to effector T cells, memory 
T cells require antigen stimulation to function.  In response to a secondary infection and 
antigen stimulation, Tcm lack immediate effector function but can develop the phenotype 
and function of effector memory T cells rapidly whereas Tem can exert immediate effector 
functions and do not need to undergo further differentiation.  After stimulation, both 
subsets produce IFN-γ and TNF-α but Tcm produce more IL-2, which is thought to increase 
their proliferative ability (Woodland and Kohlmeier, 2009). 
 
Table 1.2 summarises the phenotypic properties that differentiate naïve, effector and 
memory T cells. 
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 Naïve Effector Memory 
Small Large Small 
CD25: IL-2 receptor α chain CD25
lo
 CD25
hi
 CD25
lo
 
CD44: adhesion marker CD44
lo
 CD44
hi
 CD44
hi
 
CD62L: leukocyte adhesion molecule CD62L
+
 CD62L
-
 CD62L
-
 (Tem) or CD62L
+ 
(Tcm) 
CCR7: chemokine receptor CCR7
+
 CCR7
-
 CCR7
-
 (Tem) or CCR7
+
 (Tcm) 
CD127: IL-7 receptor α chain CD127
hi
 CD127
lo
 CD127
hi
 
Table 1.2 Distinguishing phenotypic properties of naïve, effector and memory CD4+ T 
cells, adapted from (Moulton and Farber, 2006; Sallusto et al., 1999). 
 
1.1.4.1 Tissue-specific T cell homing 
As mentioned above (section 1.1.4), naïve T cells and Tcm preferentially migrate to 
secondary lymphoid organs.  Effector T cells and Tem, in contrast, migrate to non-lymphoid 
tissues such as the gut lamina propria, lungs, skin, liver and sites of inflammation (Mora, 
2008).  They preferentially migrate to the non-lymphoid tissues that are connected to the 
secondary lymphoid organs in which antigen was first encountered.  For example, oral 
antigens, which are first encountered by GALT, induce effector T cells and Tem that express 
the cell-surface molecules needed for homing to mucosal surfaces such as the small 
intestine (Mora et al., 2003).  These cell-surface molecules are the integrin α4β7 which 
binds to mucosal vascular addressin cell adhesion molecule 1 (MAdCAM1) and the 
chemokine receptor CCR9 which interacts with the gut-associated chemokine CCL25 
(Woodland and Kohlmeier, 2009).  This gut-specific homing is imprinted on T cells by 
dendritic cells in GALT (Mora et al., 2003).  These dendritic cells produce the vitamin A 
(retinol) metabolite, retinoic acid, which induces the expression of α4β7 and CCR9 on T 
cells (Iwata et al., 2004). 
 
The integrin α4β7 is also important for T cell homing to the colon.  However, there are no 
CCR9+ T cells in the colon and CCL25 is not expressed in this compartment.  The chemokine 
CCL28 is expressed by colonic epithelial cells, but its receptor, CCR10, has not yet been 
reported on colonic T cells; it has only been found on mucosal antibody-secreting cells 
(Mora, 2008). 
1.1.5 Assays for measuring cellular immune responses 
The activation of antigen-specific T cells by antigen-presenting cells results in a number of 
biological events including the production and secretion of cytokines and the proliferation 
of antigen-specific clones (Godoy-Ramirez et al., 2004).  Numerous techniques are available 
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for the detection and measurement of these biological events and these techniques fall 
into one of two categories: bulk assays or single-cell assays. 
In a bulk assay, immune responses are analysed by averaging data from large groups of 
cells rather than by looking at individual cells.  Consequently, such assays make the 
assumption that cells of a given phenotype show identical behaviour.  Bulk assays cannot 
distinguish between whether a certain effect results from a small, homogenous response 
from all cells or a large response from a subset of cells, for example (Lindstrom and 
Andersson-Svahn, 2010).  Bulk assays used to measure T cell function include the enzyme-
linked immunosorbent assay (ELISA) and the [3H] thymidine proliferation assay (Gauduin, 
2006). 
Single-cell assays measure immune responses from individual cells.  A commonly used 
method for single-cell analysis is flow cytometry, a method which allows for the analysis of 
hundreds of thousands of individual cells per minute based on cellular properties such as 
size, granularity and fluorescence (Lindstrom and Andersson-Svahn, 2010).  Flow 
cytometric T cell assays include the intracellular cytokine staining (ICS) which measures 
cytokine production and secretion and the carboxyfluorescein succinimidyl ester (CFSE) 
proliferation assay which measures cell division.   
The ICS assay is based on the principle that T cells respond to antigen stimulation by 
releasing cytokines.  Cytokines play an essential role in the initiation and maintenance of 
the immune response and different cytokines lead to the selection and propagation of 
different effector mechanisms (Godoy-Ramirez et al., 2004).  In this assay, T cells are 
incubated with an antigen of interest.  After 1-2 hours, brefeldin A is added.  Brefeldin A 
blocks secretory pathways and therefore causes cytokine accumulation within the cell.  
After 6-24 hours, cells are harvested and stained extracellularly for phenotypic markers.  
Cells are then permeabilised and fixed, allowing intracellular staining by fluorochrome-
conjugated antibodies that are specific to the cytokines of interest.  Acquisition on a flow 
cytometer can then take place (Letsch and Scheibenbogen, 2003).   
The CFSE assay is based on the principle that T cells respond to antigen stimulation by 
undergoing mitotic cell division and rapidly increasing in number.  In this assay, cells are 
labelled with CFSE and then incubated with an antigen of interest.  CFSE is a dye that is 
taken up by T cells and partitioned equally between daughter cells following cell division.  
The intracellular CFSE is therefore diluted in each subsequent generation (Lyons, 2000).  
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After a week the cells are harvested, stained extracellularly for phenotype and the sample 
is acquired on a flow cytometer. 
The major advantage of flow cytometry is that it enables the analysis of multiple 
parameters per cell.  In the ICS assay, for example, cytokine and cell-surface markers can be 
measured simultaneously meaning that more information is obtained from a single 
specimen.  This is especially advantageous when the amount of specimen material is 
limited.   In addition, ICS allows for the simultaneous measurement of multiple cytokines 
from the same cell meaning that the chance of detecting antigen-specific cells is increased 
(Bolton and Roederer, 2009).  
As with all techniques, flow cytometry has some weaknesses.  First, the number of antigen-
specific cytokine-producing T cells is low and, consequently, difficult to detect (Godoy-
Ramirez et al., 2004).  This raises the question of how many single cells should be 
investigated and acquired on the flow cytometer in order to be confident in the conclusions 
drawn from the data.  Second, the method by which cells are processed prior to acquisition 
on a flow cytometer can alter their phenotype.  Third, T cell activation can lead to the 
down-regulation of surface markers such as CD4 and flow cytometric phenotyping relies on 
the expression of such surface markers.  For example, if CD4 is down-regulated on 
peripheral blood mononuclear cells (PBMCs) that are expressing IFN-γ, one might arrive at 
the conclusion that IFN-γ is produced by CD4- T cells, such as natural killer cells or CD8+ T 
cells (Pala et al., 2000).  Lastly, even though in principal flow cytometry allows for the 
measurement of multiple cytokines simultaneously, the time course and therefore the 
optimal detection time for different cytokines varies, and this limits investigation of co-
expression of different cytokines in single cells (Pala et al., 2000). 
1.2 TYPHOID FEVER 
Typhoid fever is a systemic infection which is caused by the bacterium Salmonella enterica 
serovar Typhi (S. Typhi).  Annually, there are an estimated 16-33 million new typhoid fever 
cases and 500,000-600,000 deaths worldwide (Ivanoff et al., 1994; Plotkin and Orenstein, 
2004).  S. Typhi is a human-specific pathogen and is transmitted via the ingestion of food 
and water contaminated by faecal or urinary carriers excreting S. Typhi.  Other sources of 
infection include vegetables fertilised by night soil and eaten raw, and shellfish taken from 
sewage-contaminated beds (Girard et al., 2006).  In the 19th century, typhoid fever was an 
important cause of illness and death in the United States and Europe due to overcrowding 
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and unsanitary urban conditions.  However, the provision of clean water and good sewage 
systems at the turn of the 20th century resulted in a dramatic decrease in the incidence of 
typhoid in these regions (Parry et al., 2002).  Today, typhoid remains endemic in most of 
the less developed areas of the world, including many countries in Africa, Asia and South 
America (Crump et al., 2004; Crump and Mintz, 2010). 
1.2.1 Molecular and biological features 
Isolates of S. Typhi often share common antigenic determinants: the protein flagellar 
antigen, H, the lipopolysaccharide antigens O9 and O12, and the polysaccharide capsular Vi 
(virulence) antigen (Girard et al., 2006).   
The complete genome sequence of a multidrug-resistant strain of S. Typhi (CT18) was 
determined in 2001 and CT18 was found to contain 4,809,037 base pairs.  Over two 
hundred pseudogenes are present in the genome of S. Typhi, a feature which is thought to 
contribute to its human-restricted host range (Parkhill et al., 2001). 
In the genome of S. Typhi, the genes for virulence factors cluster into pathogenicity islands.  
SPI-1 and SPI-2 are the two major pathogenicity islands and they encode the type three 
secretion system (TTSS) which is responsible for the translocation of bacterial virulence 
proteins into host cells during infection (Zhang et al., 2008).  SPI-1 encodes the TTSS and its 
effectors which are required for the invasion of epithelial cells.  It is thought to be activated 
under conditions present in the intestinal lumen before host cell invasion such as high 
osmolarity and low aeration (Faucher et al., 2009).  SPI-2 encodes a second TTSS, effector 
proteins, molecular chaperones and a regulatory system that activates SPI-2 promoters, 
and is essential for intracellular survival and replication at systemic sites of infection (Zhang 
et al., 2008).  It is activated intracellularly and SPI-2 TTSS genes are induced by an acidic pH 
and low concentrations of magnesium and phosphate (Faucher et al., 2009). 
S. Typhi has many other pathogenicity islands, most of which are of great importance to 
the virulence and survival of the bacterium.  SPI-7 encodes the genes for Vi polysaccharide 
capsule production.  This capsule is thought to be important in the survival of the 
bacterium within macrophages (Zhang et al., 2008).  SPI-7 is a mobile and potentially 
unstable genetic region and this could have important implications for the Vi-based 
polysaccharide typhoid vaccine; capsule replacement events could occur as a result of 
selection driven by Vi-based mass-vaccination campaigns (Baker and Dougan, 2007). 
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1.2.2 Pathogenesis 
S. Typhi is ingested in contaminated water or food and must pass through the acid stomach 
in order to reach the small intestine.  Once in the small intestine, typhoid bacilli must 
adhere to mucosal cells and then penetrate the gut mucosa (Parry et al., 2002).  Active 
attachment to mucosal cells is promoted by the bacilli and is thought to involve adhesion 
molecules on the bacteria interacting with receptors on the host cell, an interaction which 
may involve fimbriae (House et al., 2001).  Invasion of mucosal cells is mediated by SPI-1 
and SPI-2.  SPI-1 encodes regulator proteins, a TTSS which delivers bacterial proteins into 
the host cell, and effector proteins which bring about changes in the host cell and promote 
bacterial uptake (House et al., 2001).   
 
There are four different ways in which typhoid bacilli can penetrate the mucosal epithelium 
to reach the lamina propria: (1) bacilli are actively taken up by M cells, the specialised 
epithelial cells which are found overlying Peyer’s patches, (2) bacilli are taken up by 
normally non-phagocytic enterocytes as a result of Salmonella’s SPI-1 and other invasive 
mechanisms, (3) Salmonella can cross the epithelium paracellularly and (4) direct uptake of 
Salmonella from the gut lumen by dendritic cells in the lamina propria which are able to 
extend dendrites through the basement membrane and between the epithelial cells to 
enter the gut lumen (Biedzka-Sarek and El Skurnik, 2006).  This latter route involves the 
transport of Salmonella from the gastrointestinal tract to the bloodstream.  Consequently, 
it does not induce mucosal immunity but is thought to be important for the induction of 
systemic immunity to gastrointestinal pathogens (Vazquez-Torres et al., 1999). 
 
Following penetration of the mucosal epithelium, typhoid bacilli elicit an influx of 
macrophages which ingest the organisms but do not kill them.  Salmonella reside within 
macrophages in specialised compartments known as Salmonella-containing vacuoles 
(Alpuche-Aranda et al., 1994).  Some bacilli remain within macrophages in the small 
intestine lymphoid tissue whilst others are drained into MLNs where further ingestion by 
macrophages occurs.  Shortly after invasion of the intestinal mucosa, primary bacteraemia 
occurs (Plotkin and Orenstein, 2004).  Some bacilli then pass to the reticuloendothelial 
tissue of the liver and spleen where they are able to survive and multiply.   
 
After about 8 to 14 days, S. Typhi are released from their intracellular location, resulting in 
secondary bacteraemia, fever and systemic infection (Gordon, 2008).  Haematogenous 
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spread means that S. Typhi is widely disseminated and able to infect a number of sites 
(Figure 1.3).  The most common sites of secondary infection are the liver, spleen, bone 
marrow, gallbladder and Peyer’s patches.  Gallbladder invasion occurs directly from the 
blood or by retrograde spread from the bile (Parry et al., 2002).  In 2% to 5% of cases, 
gallbladder infection becomes chronic (Plotkin and Orenstein, 2004).  Bacilli which are 
excreted in the bile either reinvade the intestinal wall or are shed in the faeces, an essential 
step in the transmission of typhoid fever (Parry et al., 2002). 
 
 
Figure 1.3 The pathogenesis of typhoid fever from (Gordon, 2008). 
1.2.3 Clinical features 
Typhoid fever is characterised by fever and abdominal symptoms.  Nonspecific symptoms 
are often present before the onset of fever.  Such symptoms include cough, sore throat, 
headache, dizziness, loss of appetite, chills, perspiration, diarrhoea or constipation, and 
muscle pains.  Other symptoms include splenomegaly, hepatomegaly, bradycardia and rose 
spots (Fraser et al., 2007).  Complications occur in 10% to 15% of patients and are more 
likely in patients who have been ill for more than a fortnight.  The most important 
complications are gastrointestinal bleeding, intestinal perforation and typhoid 
encephalopathy (Parry et al., 2002).  Gastrointestinal bleeding is the most common 
complication, occurring in up to 10% of patients.  It is the result of erosion of a necrotic 
Peyer’s patch through the wall of an enteric vessel.  In the majority of cases the bleeding is 
not severe but in 2% of cases, bleeding is clinically significant and can be rapidly fatal (Parry 
et al., 2002).   
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In the pre-antibiotic era, the case-fatality rate for typhoid fever was 10-20%.  The use of 
antibiotics such as chloramphenicol to treat typhoid fever saw case fatality drop to below 
1%.  However, the emergence of antibiotic-resistant strains of S. Typhi in several parts of 
the world during the last decade of the twentieth century has led to an increase in the 
incidence of severe cases and an increase in typhoid mortality (Plotkin and Orenstein, 
2004). 
1.2.4 Vaccination 
There are three currently licensed typhoid vaccines available: inactivated phenol-preserved 
whole-cell parenteral vaccine, purified Vi polysaccharide parenteral vaccine and attenuated 
S. Typhi strain Ty21a which is used as a live oral vaccine. 
 
1.2.4.1 Parenteral inactivated whole-cell vaccine 
The first parenteral whole-cell typhoid vaccine was introduced in 1896 but it was not until 
the 1960s that its efficacy was established in field trials (Parry et al., 2002).  Although these 
vaccines are efficacious, high rates of systemic and local adverse reactions make them 
unsuitable for use as public health tools and they have generally been abandoned 
(Garmory et al., 2002).  
 
1.2.4.2 Purified Vi polysaccharide parenteral vaccine 
The subunit Vi vaccine was developed in the 1980s (Girard et al., 2006).  The Vi capsular 
polysaccharide is an important virulence factor.  As well as preventing antibodies from 
binding to the O antigen, which allows S. Typhi to survive in the blood, it is associated with 
both the inhibition of complement activation and resistance to complement-mediated lysis 
and phagocytosis (Garmory et al., 2002; Looney and Steigbigel, 1986).  This vaccine is 
administered as a single subcutaneous or intramuscular injection and is both safe and 
effective (Fraser et al., 2007). 
 
Vi-based subunit vaccines have three main drawbacks: they are unable to stimulate 
mucosal immunity, revaccination does not elicit any booster effect, and they do not protect 
young children.  Absence of a booster effect occurs as immune responses against 
polysaccharides do not involve T cells and so immunological memory cannot be 
established.  A lack of effective protection in children younger than two years occurs as 
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young children cannot mount effective immune responses to bacterial polysaccharides 
(Guzman et al., 2006). 
 
These limitations could be overcome by using a conjugate vaccine in which the T-
independent Vi polysaccharide antigen was linked to a T-dependent protein carrier.  Such a 
vaccine, in which Vi polysaccharide is covalently bound to recombinant Pseudomonas 
aeruginosa exotoxin A, is under development but is not yet licensed (Guzman et al., 2006).  
This vaccine, known as Vi-rEPA, was evaluated in a randomised control trial in children two 
to five years old in Vietnam where its efficacy was found to be 91.5% (Lin et al., 2001).  It 
has recently been evaluated in infants (two to twelve months) and was found to be safe, 
compatible with the Expanded Program on Immunisation vaccines and able to induce 
protective anti-Vi antibodies (Thiem et al., 2011).  Currently, conjugate vaccines are 
licensed for use against pathogens such as Haemophilus influenzae type b, Neisseria 
meningitidis and Streptococcus pneumoniae (Guzman et al., 2006).  
 
1.2.4.3 Ty21a live oral vaccine 
Ty21a was developed in the 1970s by chemical mutagenesis of the wild-type strain Ty2 and 
has a GalE- and Vi-negative phenotype (Germanier and Fuer, 1975).  The galE gene encodes 
the enzyme uridine diphosphate (UDP)-galactose-4-epimerase, an enzyme which is 
responsible for the conversion of UDP-glucose to UDP-galactose and vice versa.  A GalE-
negative phenotype therefore results in the absence of this enzyme, with the result that 
UDP-galactose cannot be metabolised.  When galactose is present in the growth medium, 
UDP-galactose therefore accumulates in the cytoplasm, causing cell lysis and attenuation 
(Guzman et al., 2006).  When galactose is not present in the growth medium, Ty21a does 
not express smooth O antigen in its lipopolysaccharide (LPS) because it has no source of 
galactose and in this state it is not virulent or immunogenic.  Ty21a is therefore supplied 
with exogenous galactose during vaccine production (Guzman et al., 2006).  As a result of 
nonspecific chemical mutagenesis, other mutations are also present within strain Ty21a but 
not all of these are characterised (Dietrich et al., 2003). 
 
Ty21a (Vivotif®) is manufactured by Crucell and contains lyophilised S. Typhi Ty21a, with not 
less than 2 x 109 viable cells per capsule.  It is recommended for adults and children from 
six years of age.  Throughout the world (with the exception of the USA and Canada) a 
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three-dose oral immunisation schedule is recommended, with one capsule being taken on 
days one, three and five, with lukewarm water at least one hour before meals.  Protection 
becomes effective about seven to ten days after the last dose (Plotkin and Orenstein, 2004) 
(Appendix 1).  Contraindications to immunisation with Ty21a include hypersensitivity to any 
components (e.g. gelatine), immune deficiency, concomitant treatment with 
immunosuppressive drugs, pregnancy, certain antibiotics and acute febrile or 
gastrointestinal illness (Plotkin and Orenstein, 2004)(Appendix 1).  
The efficacy of the Ty21a vaccine has been evaluated in many clinical trials.  These have 
shown variable protective efficacy, ranging from 96% in Egypt after three years (Wahdan et 
al., 1982) to 67% in Chile after three years (Levine et al., 1999) to 42% in Indonesia after 
two and a half years (Simanjuntak et al., 1991).  In a meta-analysis, the three year 
cumulative efficacy of Ty21a was found to be 51% (Engels et al., 1998). 
Ty21a is an extremely safe and well-tolerated vaccine, a fact which has been confirmed in 
more than 200 million vaccinees during over 20 years of use worldwide.  Between 1990 and 
2000, over 38 million people were vaccinated with Ty21a and there were only 743 reports 
of adverse effects, an incidence of 0.002% (Guzman et al., 2006).  The most common 
adverse effects reported were mild gastrointestinal disturbances and general symptoms, 
such as fever (Guzman et al., 2006).  Upon administration of the vaccine, there is either a 
limited and transient level or a complete lack of faecal excretion of Ty21a (Levine et al., 
2001).  Genetic attenuation combined with low shedding rate significantly reduces the 
environmental risks posed by the use of Ty21a (Guzman et al., 2006). 
1.2.4.4 Newer generation unlicensed oral vaccines 
Drawbacks of the Ty21a vaccine, such as the requirement for multiple doses to elicit a 
protective response and incomplete protection, led to the development of a number of 
novel live attenuated S. Typhi strains during the last three decades (Guzman et al., 2006), 
although none of these strains are currently licensed as typhoid vaccines.  Novel strains 
include Ty800, Centre for Vaccine Development (CVD) 908, CVD 908-htrA, CVD 909 and 
M01ZH09.  Ty800 is a derivative of S. Typhi strain Ty2 which is mutated in phoP/phoQ, two 
virulence-regulating genes.  In clinical trials this strain induced vigorous immune responses 
without adverse side effects, apart from diarrhoea in a small number of individuals 
(Hohmann et al., 1996).   
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Strains CVD 908, CVD 908-htrA and CVD 909 are all based on mutations in aroC and aroD, 
genes whose function is the biosynthesis of para-aminobenzoic acid, 2,3-
dihydroxybenzoate and aromatic amino acids (Mastroeni et al., 2001).  Salmonella with 
mutations in aro genes have impaired ability to proliferate within mammalian cells, but 
they grow intracellularly for long enough to stimulate immune responses (Tacket and 
Levine, 2007).  CVD-908 is an aroC/aroD deleted derivative of S. Typhi strain Ty2.  This 
vaccine was well tolerated after a single dose and six out of twelve volunteers developed 
serum IgG anti-lipopolysaccharide antibodies whilst IgA anti-LPS antibody-secreting cells 
were detected in nine of eleven volunteers (Tacket et al., 1992).  However, subsequent 
clinical studies found that clinically silent, self-limited vaccine bacteraemia occurred in 
between 50-100% of volunteers depending of the dose of organism given and this was 
thought to be an indicator of unacceptable reactogenicity in future studies which could 
involve larger numbers of volunteers, not all of who would be healthy adults (Tacket and 
Levine, 2007). 
A deletion in the htrA gene was introduced into CVD 908 to yield the strain CVD 908-htrA.  
The htrA gene encodes a heat-shock protein and when this gene is deleted, the resulting 
mutant is less virulent due to a reduced ability to survive and replicate in host tissues 
(Tacket and Levine, 2007).  CVD 908-htrA retained the immunogenicity of CVD 908 but no 
vaccine bacteraemia was detected.  A single dose of CVD 908-htrA stimulated strong 
mucosal, humoral and cellular immune responses that were equal or better than those 
measured after multiple doses of Ty21a (Tacket et al., 2000b). 
A drawback of both CVD 908 and CVD 908-htrA was an inability to consistently stimulate 
serum Vi antibody.  The viaB locus of S. Typhi encodes the genes needed for the synthesis, 
surface transport and anchoring of Vi.  Strain CVD 909 was produced by replacing the 
promoter PtviA (the most upstream gene in the viaB locus of CVD 908-htrA) with the strong 
constitutive promoter Ptac (Wang et al., 2000).  CVD 909 was found to be safe in a phase I 
clinical trial but while strong gut-derived IgA antibody-secreting cell responses were 
induced against Vi-antigen, only two out of 32 vaccinees exhibited anti-Vi IgG in serum 
(Tacket et al., 2004). 
M01ZH09 is a single-dose candidate vaccine with two well-defined attenuating mutations.  
There is a mutation in a structural protein (SsaV) of SPI-2 which destroys the function of 
SPI-2, preventing the systemic spread of S. Typhi, and an aromatic mutation (aroC-) which 
deprives the bacterium of essential nutrients that it obtains from the human host 
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(Kirkpatrick et al., 2005).  This vaccine has been showed to be safe and immunogenic in 
Western adult volunteers (Hindle et al., 2002).  In 2010, the results of a phase II trial of 
M01ZH09 in children in Vietnam, an endemic country, were published (Tran et al., 2010).  
The vaccine had an appropriate safety profile and a positive immune response was 
detected in 98 out of 101 vaccinated children. 
1.3 ADAPTIVE IMMUNE RESPONSES TO SALMONELLA TYPHI 
1.3.1 Immune response to natural S. Typhi infection 
Natural infection with S. Typhi induces humoral and cellular immune responses.  Humoral 
responses include serum antibodies against bacterial antigens such as O-antigen 
(lipopolysaccharide), H-antigen (flagellar component) and Vi polysaccharide capsular 
antigen, and secretory IgA (sIgA) against bacterial antigens such as O-antigen.  sIgA is found 
in intestinal fluids and bile.  Cell-mediated responses in the blood include T cell 
proliferation and increased levels of Th1-type cytokines such as IFN-γ, TNF-α, IL-1 and IL-6 
(Pasetti et al., 2011).  Little is known about the mucosal cell-mediated immune (CMI) 
response to natural infection. 
1.3.2 Immune response to vaccination with the Vi polysaccharide vaccine 
Vaccination with the parenteral Vi polysaccharide vaccine stimulates the production of 
systemic antibodies (mainly IgG and IgA) against the Vi capsular antigen only (Pasetti et al., 
2011).  No cell-mediated immune response is induced by this vaccine because 
polysaccharides are T-cell-independent antigens.   
1.3.3 Immune response to vaccination with Ty21a 
Vaccination with Ty21a differs from natural infection because Ty21a does not express the 
Vi polysaccharide capsular antigen and is consequently unable to stimulate Vi antibody 
(Levine et al., 2001).  Additionally, Ty21a differs from its wildtype parent, the pathogenic S. 
Typhi strain Ty2, by more than two dozen mutations (Pasetti et al., 2011).  However, as 
with natural infection, oral vaccination can activate every effector arm of the immune 
system and both humoral and cell-mediated systemic and mucosal immune responses are 
elicited.  Serum IgG against O-antigen is induced (D'Amelio et al., 1988; Viret et al., 1999) as 
well as antibodies against a number of proteins including H-antigen, porins, outer 
membrane proteins, heat-shock proteins, flagella and fimbriae (Mastroeni et al., 2001).  
Locally, intestinal secretory antibodies are induced against O-antigen (Ivanoff et al., 1994; 
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Levine et al., 2001).  The Ty21a vaccine stimulates strong cell-mediated CD4+ and CD8+ 
immune responses.  In the blood, there is T cell proliferation and the production and 
secretion of Th1-type cytokines such as IFN-γ (Table 1.3).  Nothing is known about the CMI 
responses that are induced locally in the gut mucosa (Sztein, 2007). 
 
Study Methods Systemic cellular response Mucosal 
cellular 
response 
(Salerno-
Goncalves et 
al., 2002) 
Flow cytometry, 
ELISPOT 
Significant increase in IFN-γ production in 
4/5 individuals.  IFN-γ secreted 
predominantly from CD8
+
 T cells 
- 
(Lundin et al., 
2002) 
ELISA, [
3
H]thymidine Significant (>2-fold) increase in rate of 
proliferation and IFN-γ production in 6/8 
individuals.  IFN- γ secreted predominantly 
from CD8+ T cells 
- 
(Kilhamn et 
al., 2003) 
ELISA, [
3
H]thymidine CD4
+
: significant (> 2-fold) proliferative 
response and IFN-γ production in 3/10 
individuals 
CD8
+
: significant (> 2-fold) proliferative 
response and IFN-γ production in 6/10 
individuals  
- 
(Lundgren et 
al., 2009) 
ELISA, Pelikine 
compact human 
granzyme A and B kits, 
[
3
H]thymidine 
Vaccinees responded with significantly 
(>2-fold) increased levels of IFN-γ (8/11) 
and granzyme A (7/11) but not granzyme 
B.  Significantly increased proliferative 
response (7/15) 
- 
(Viret et al., 
1999) 
ELISA, [
3
H]thymidine  CD4
+
: Significantly increased proliferative 
responses and IFN-γ production in 5/5 
individuals 
- 
Table 1.3 A summary of studies measuring cellular immunological responses to the live 
oral typhoid vaccine Ty21a in humans.  In all studies, individuals were vaccinated with 
three doses of Ty21a at two day intervals except (Salerno-Goncalves et al., 2002) in which 
individuals were vaccinated with four doses of Ty21a at two day intervals 
1.4 VECTOR VACCINES 
The majority of pathogens enter the body through the mucous membranes (Czerkinsky and 
Holmgren, 2009).  For this reason, mucosally-delivered vaccines, which have the potential 
to elicit both systemic and mucosal immune responses, have an advantage over parenteral 
vaccines, which induce a systemic response but have limited capacity to induce a mucosal 
response.  Antigens delivered by the oral mucosal route are exposed to the acidity of the 
gastrointestinal tract and can be degraded by enzymes at mucosal surfaces; for these 
reasons, such antigens are often poorly immunogenic.  This issue can be overcome by using 
live bacteria as vectors.  Bacteria can be engineered to express antigens from unrelated 
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pathogens and deliver these heterologous antigens to the immune system, leading to the 
generation of mucosal and systemic immune responses (Garmory et al., 2003).  If the 
concept of a common mucosal immune system is taken as fact, the generated immune 
response would be present at both the immune inductive site in which antigen 
presentation occurred and at remote mucosal sites (Medina and Guzman, 2001). 
Attenuated strains of S. Typhi and Salmonella enterica serovar Typhimurium (S. 
Typhimurium) can be used as live vector vaccines.  Salmonella strains are suited to this role 
because they can be administered orally (natural route of infection), they are transported 
through M cells to GALT (immune inductive site), they are readily taken up by antigen-
presenting cells such as dendritic cells and macrophages and they stimulate a wide array of 
systemic and mucosal humoral and cellular immune responses (Galen et al., 2009).  
Salmonella are also easy to genetically manipulate (Garmory et al., 2002).  Potential 
problems of live bacterial carriers include reversion to virulence or reactogenicity, stability 
of the recombinant phenotype and horizontal gene transfer between the vaccine strain and 
mucosal or environmental microorganisms (Medina and Guzman, 2001).  There is also the 
issue of pre-existing immunity.  Prior immunity to S. Typhi, for example, may adversely 
affect the magnitude of the immune response against the heterologous antigens. 
S. Typhimurium infection of rodents closely resembles S. Typhi infection of humans (Pasetti 
et al., 2003).  Preclinical work using a Typhimurium mouse model has highlighted the 
potential of Salmonella vector vaccines.  For example, DiGiandomenico et al. (2004) orally 
vaccinated BALB/c mice with attenuated S. Typhimurium expressing Pseudomonas 
aeruginosa serogroup O11 O antigen.  Vaccination stimulated the production of O11-
specific IgG and IgA antibodies in serum and remotely in bronchoalveolar lavage fluid (BAL).  
When orally vaccinated mice were challenged with an O11 strain of P. aeruginosa at six and 
twelve times the 50% lethal dose, survival was increased compared to the control group.  
Vaccinated mice also demonstrated an ability to clear the bacteria from their lungs 
(DiGiandomenico et al., 2004).  Live recombinant S. Typhimurium vaccines expressing 
pneumococcal proteins such as pneumococcal surface protein A have also been developed.  
Vaccination of mice with these vaccines elicited serum IgG and mucosal IgA responses.  
Furthermore, vaccinated mice were protected against intraperitoneal, intravenous and 
intranasal pneumococcal challenge (Xin et al., 2009). 
S. Typhi is a human-restricted pathogen and, consequently, it is not known to be virulent in 
any animal model after oral vaccination (Garmory et al., 2002).  However a mouse model of 
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intranasal immunisation exists.  Mice were immunised via the intranasal route with the live 
attenuated S. Typhi strain CVD 908-htrA expressing fragment C of tetanus toxin.  In addition 
to the detection of humoral and cell-mediated systemic responses against fragment C, a 
mucosal response was also seen; both IgG and IgA fragment C-specific antibody-secreting 
cells were demonstrated in the lung (Capozzo et al., 2004).  Recently, a humanised mouse 
has been developed for the study of typhoid fever.  Nonobese diabetic-scid IL2rγnull mice 
were engrafted with human haematopoietic stem cells (hu-SRC-SCID mice).  S. Typhi was 
able to replicate in these mice, causing a lethal infection with pathological and 
inflammatory features that resembled human typhoid fever (Libby et al., 2010).  This 
humanised mouse model will be invaluable for understanding more about the 
pathogenesis of S. Typhi and for identifying vaccine candidates that could lead to the 
prevention of typhoid fever. 
There have only been a small number of human clinical trials of S. Typhi vector vaccines.  
Gonzalez et al. (1994) vaccinated individuals with the S. Typhi strain CVD 908 expressing 
the circumsporozoite protein (CSP) of Plasmodium falciparum and they demonstrated a 
serologic and mucosal IgA response to CSP (Gonzalez et al., 1994).  This was the first clinical 
trial of its kind.  More recent clinical trials have used antigens from Helicobacter pylori 
(Metzger et al., 2004) and Clostridium tetani (Tacket et al., 2000a).  In general, the immune 
responses detected in such trials have been weak.  Galen et al. conclude that this is 
because ‘no trial has tested a robust live vector strain that expresses an antigen of 
predictable immunogenicity (based on other vaccine or natural infection experience) from 
a stabilized gene (chromosomal or state-of-the-art plasmid maintenance system), under a 
suitable promoter and (critically!) with either surface expression or export of the antigen 
out of the bacteria.  Thus, to date, no clinical trial has been carried out with an optimum 
construct’ (Galen et al., 2009). 
1.5 RATIONALE AND AIMS  
Ty21a is the only licensed live oral typhoid vaccine and it has been licensed for many 
decades.  Despite this, very little is known about the cellular immune responses elicited 
locally in the intestinal mucosa after vaccination.  A better understanding of these local 
immune responses and how well they correlate with systemic immune responses would 
inform the development of future vaccines, which relies on the measurement of the 
systemic immune response to evaluate vaccine candidates.   
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The concept of a common mucosal immune system means that oral vaccines could be 
developed which could elicit immune responses at remote mucosal sites.   The use of 
Salmonella as vector vaccines has shown great promise in animal models but more work 
needs to be done in humans to see how effective such vaccines are. 
Aims: 
 To determine whether vaccination with Ty21a induces antigen-specific CD4+ T cells 
in peripheral blood, duodenum and colon 
 To determine whether there is  a relationship between the magnitude of the 
antigen-specific response in duodenum compared to colon or blood 
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CHAPTER 2: STUDY DESIGN, MATERIALS AND METHODS 
2.1 STUDY LOCATION 
This study was conducted in Liverpool and was sponsored by the Royal Liverpool University 
Hospital (RLUH) and the Liverpool School of Tropical Medicine (LSTM).  The clinical work 
was carried out at the RLUH and the laboratory work was carried out at the LSTM.  
2.2 STUDY POPULATION 
Study participants were recruited by poster advertisement (Appendix 2) around the 
University of Liverpool (UoL) campus, RLUH and LSTM and by electronic advertisement of 
the intranet of UoL.  Seventeen healthy adult study participants (median age 26 years, age 
range 21-58 years, 9 females) were enrolled in the study after they had given informed 
consent.   
2.2.1 Inclusion and exclusion criteria 
The inclusion and exclusion criteria for participation in the study were as follows:  
 Inclusion criteria for control and vaccinated groups: 
o Adults aged between eighteen and sixty years 
o Adults in full health (to minimise the risk of the vaccination or the 
procedures) 
o Fluent spoken English (to ensure that volunteers understand the purpose 
of the research project and their role within it and are able to give 
informed consent) 
o Capacity to give informed consent 
 Exclusion criteria for control and vaccinated groups: 
o Pregnancy 
o Chronic illness or immunocompromise 
o Anaemia 
o Platelet count below 30,000 
o Individuals who have received the parenteral typhoid vaccine within the 
past three years or the oral typhoid vaccine within the past 12 months (the 
recommended booster intervals) 
o Smoker or ex-smoker who has smoked more than 20 cigarettes a day for 
ten years 
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o Individuals already involved in another clinical trial 
 Additional exclusion criteria for vaccinated group: 
o Previous adverse reaction to vaccination 
 
Individuals who had previously been vaccinated against typhoid outside the recommended 
booster intervals were accepted for the study as this was thought to be likely to yield useful 
information about the magnitude and character of primary compared to boosted 
responses to vaccination.  Such individuals were allocated to the vaccinated arm of the 
study. 
2.2.2 Sample size calculation 
A sample size of 21 in each group (42 in total) will have 80% power to detect a two-fold 
difference in the mean percentage of T cells showing antigen-specific intracellular IFN-γ 
production at a 0.05 two-sided significance level between unvaccinated and vaccinated 
individuals.  This calculation was based on PBMC responses to mucosally presented 
antigens such as flu and pneumococcus as the best available data are for PBMC responses 
to these antigens as opposed to mucosal responses to typhoid.  The assumption was made 
that this sample size would also be adequate for mucosal responses as one would 
anticipate that mucosal T cell responses to typhoid should be of a greater magnitude than 
PBMC responses, as typhoid is presented through the mucosa.  A 15% drop-out during the 
study was anticipated so the plan was to recruit 48 individuals in total, 24 in each group. 
2.2.3 Ethical approval 
Ethical approval for this study was obtained from the National Research Ethics Service 
(10/H1005/20) (Appendix 3) and the Liverpool School of Tropical Medicine ethics 
committee (SG10.01) (Appendix 4). 
 
The statistician that reviewed the protocol for the ethics application suggested that, given 
the invasive nature of the study, an interim analysis should be carried out after 16 subjects 
had completed the study in order to check the assumptions made in the power calculation.  
This thesis reports the results of this interim analysis. 
2.3 STUDY DESIGN 
Venous blood (30-50ml) was collected from both groups on day 0 (pre-immunisation 
sample) and day 18 (post-immunisation sample collected 14 days after the last dose of the 
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vaccine).  D2-D3 duodenal pinch biopsies were collected on day 18 from 10 vaccinees and 
seven controls.  In addition, sigmoid colonic biopsies were collected on day 18 from seven 
vaccinees and four controls (Figure 2.1). 
Day -7: recruitment and consent
Day 0: clinic visit and venesection
Day 18: clinic visit, venesection and gastroscopy +/-
sigmoidoscopy
Vaccinated group (n=10) Control group (n=7)
Day 0: Oral vaccine dose 1
Day 2: Oral vaccine dose 2
Day 4: Oral vaccine dose 3
 
Figure 2.1 Timeline showing the collection of clinical samples from volunteers. 
2.3.1 Vaccine and vaccination 
Participants were allocated to the vaccinated group if they had previously received a 
typhoid vaccine outside of the recommended booster interval.  Those who were thought to 
be totally naïve were randomly allocated to either group.   
The live attenuated oral vaccine Vivotif® was used in this study.  Vivotif® contains lyophilised 
Salmonella enterica serovar Typhi Ty21a, with not less than 2 x 109 viable cells per capsule 
(Appendix 1). 
Study participants were given three doses of the vaccine.  One capsule was taken on each 
of days 0, 2 and 4, approximately one hour before a meal with a cold or lukewarm drink.  
Participants were not observed taking doses two and three of the vaccine, but were 
reminded to take them via text message.  Verbal confirmation was received on the day of 
the endoscopic procedure. 
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2.3.2 Venepuncture 
30-50ml of blood was collected in a syringe containing sodium heparin. 
2.3.3 Endoscopy 
Individuals fasted from midnight before going to the hospital at 8am, where consent for 
endoscopic procedures was confirmed by the endoscopist.  If the individual was having a 
flexible sigmoidoscopy in addition to a gastroscopy, a Fleet(TM) phosphate liquid enema 
(133mls) was given per rectum 20 minutes before the procedure.  Sedation was optional; 
individuals who requested sedation were given up to 5mg maximum of midazolam 
intravenously.  Nasal oxygen was administered during the procedures, and pulse oximetry 
monitoring was conducted throughout the procedures.  12-15 D2-D3 duodenal single-bite 
cold biopsies and 12-15 single-bite cold biopsies from the sigmoid colon at 20-25cm 
insertion were collected using Boston Scientific large capacity ‘jumbo’ forceps which passed 
through a standard 2.8mm endoscopic biopsy channel.  Biopsies were placed in MR15 
medium1 containing antibiotics, and transported on ice prior to processing in the 
laboratory.  Individuals were observed for two hours post-procedure, given a drink and 
snack, and then discharged home. 
 
2.4 SAMPLE PROCESSING 
2.4.1 Isolation of mononuclear cells 
2.4.1.1 Isolation of peripheral blood mononuclear cells (PBMCs) 
Heparinised venous blood (30-50ml) was diluted with an equal volume of PBS.  The diluted 
blood was overlayed onto LymphoprepTM at a ratio of 2:1 and centrifuged at 836xg for 25 
minutes at 4˚C with the centrifuge brake disabled. PBMCs formed a floccular band between 
the plasma and the LymphoprepTM and this band was transferred to a new tube with a 
Pasteur pipette.  The PBMCs were washed in 50ml phosphate buffered saline (PBS) and 
spun at 470xg with the brake disabled for ten minutes at 4˚C.  They were then washed in 
30(50)ml PBS and spun at 209xg with the brake disabled for five minutes at 4˚C.  Finally, the 
                                                          
1
 MR15 medium was made by adding 50ml foetal bovine serum (FBS), 10ml 200mM L-
glutamine, 1ml Tazocin (piperacillin 250mg/ml, tazobactam 31.25mg/ml) and 2.5ml amphotericin B 
(250µg/ml) to a 500ml bottle of RPMI-1640 
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PBMCs were resuspended in 15(20)ml complete medium2 and counted.  After counting, the 
PBMCs were used for downstream applications on the same day. 
 
2.4.1.2 Isolation of mucosal mononuclear cells (MMCs) 
Biopsies were collected in 40ml MR15 medium on ice and transferred to the laboratory 
where they were centrifuged at 400xg for ten minutes at room temperature with the brake 
disabled.  The biopsy pellet was then resuspended in 12.5ml CII-S medium3 and incubated 
at a 45˚ angle in a shaking incubator for 30 minutes (37˚C, 220rpm).  After this time, the 
tissue suspension was decanted into a syringe that was attached to a 16-gauge blunt-ended 
needle and rested on an open 50ml Falcon tube.  The syringe barrel was then introduced 
and the suspension was forced through the syringe and into the Falcon tube.  This 
procedure was done to disrupt the tissue and was repeated five times.  A 70µm cell strainer 
was then placed on the trim of a Falcon tube and the disrupted cell suspension supernatant 
was passed through it.  Tissue fragments and clumps left in the cell strainer were 
transferred into the original tube by rinsing the cell strainer with 12.5ml of CII-S medium, 
ensuring that all the CII-S medium also entered the original tube.    The original tube was 
then placed back into the shaking incubator and the procedure of incubating the cells with 
collagenase and mechanically disrupting them was repeated twice more.  Whilst the tube 
containing tissue fragments was shaking, the tube containing the free cells was washed 
with 30ml MR15 medium and centrifuged at 400xg for ten minutes.  The pellet was 
resuspended in 15ml MR15 and the tube was then left on ice; this procedure was repeated 
with the free cells obtained from passages two and three.  The free cells from all three 
passages were then pooled and the tube topped up to 50ml with MR15 before being spun 
for ten minutes at 400g.  The pellet was then resuspended in 5ml MR15 and the cells were 
counted.  After counting, the cell were seeded on a 24-well plate at a concentration of one 
million cells per ml and rested overnight by incubating the plate at 37˚C, 5% CO2.  The cells 
were then used for downstream applications. 
 
This method was a modified version of that developed by the International AIDS Vaccine 
Initiative (Kaltsidis et al., 2011). 
 
                                                          
2
 Complete medium was made by adding 50ml FBS and 10ml 200mM L-glutamine to a 500ml 
bottle of RPMI-1640 
3
 CII-S medium was made by adding 50mg collagenase II-S to 100ml MR15   
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2.4.2 Cell counting 
PBMCs and MMCs were counted using an Improved Neubauer haemocytometer.  20µl of 
the cell suspension was added to 20µl of trypan blue and mixed well.  10µl of this mixture 
was then pipetted under the coverslip on one side of the haemocytometer and the number 
of viable lymphocytes or macrophages (cells excluding the trypan blue stain) were counted 
in the green squares shown on the diagram below (Figure 2.2). 
 
 
 
Figure 2.2 The grid of an improved Neubauer haemocytometer.  The cells than were 
counted are shown in green. 
 
The number of cells per ml was calculated as follows: 
Total number of counted cells * 2(dilution factor) * 104(multiplication factor) 
            4 
2.5 FUNCTIONAL T CELL ASSAYS 
Flow cytometry was used to assess antigen-specific cellular immune responses.  Two 
functional T cell assays were used; an intracellular cytokine staining (ICS) assay and a CFSE 
lymphoproliferation assay.   
2.5.1. Antigens used for stimulation 
The antigens used for stimulation in the functional T cell assays were: 
 Staphylococcal enterotoxin B (SEB) - SEB is an exotoxin excreted by the bacterium 
Staphylococcus aureus and it is commonly associated with food poisoning in 
humans (Bergdoll et al., 1974).  SEB is a superantigen, meaning that it possesses 
extremely potent stimulatory activity on T lymphocytes (Liu et al., 2006), causing 
the release on massive amounts of cytokine.  This therefore makes it ideal as a 
positive control for the intracellular cytokine staining assay.  
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 Phytohaemagglutinin (PHA) - PHA is a plant extract and a T cell mitogen (Nowell, 
1960); its ability to trigger cell division in T lymphocytes makes it ideal as a positive 
control for the lymphoproliferation assay. 
 Influvac® sub-unit - Influvac® is an inactivated influenza vaccine.  The active 
substances in the vaccine are haemagglutinin and neuraminidase antigens of three 
different Influenza viruses. 
 Vivotif® - The original vaccine strain, Ty21a, was used for stimulation.  A stock of 
heat-killed Ty21a was made by dissolving two vaccine capsules in 4ml of PBS.  The 
solution was divided into four Eppendorf tubes and these were placed in a heating 
block at 95˚C for 30 minutes.  Pilot work showed that this was the minimum 
amount of time needed to kill all of the bacteria in the vaccine.  After this time, 
some of the suspension from each Eppendorf was plated onto Columbia blood agar 
plates and incubated overnight at 37˚C.  The plates were clear the following 
morning, indicating that the heat treatment had killed the bacteria.  The solution in 
the four Eppendorf tubes was then pooled, shaken and distributed among a 
number of Eppendorf tubes which were stored as stock at -70˚C. 
These four antigens were titrated using the CFSE lymphoproliferation assay to determine 
the optimal volume to use for cell stimulation. 
2.5.2 Intracellular cytokine staining assay 
Antigen-specific cytokine-producing T cells can be detected using an ICS assay.  Briefly, this 
assay involves incubating T cells with antigen, adding the protein transport inhibitor 
brefeldin A to cause cytokine accumulation within cells, and permeabilising the cells to 
allow anti-cytokine fluorescent antibody conjugates to enter them and bind to any 
accumulated cytokine (Letsch and Scheibenbogen, 2003).   Cytokine production is then 
analysed using a flow cytometer.  Flow cytometry allows for the simultaneous 
measurement of multiple cytokines from the same cell meaning that the chance of 
detecting antigen-specific cells is increased (Bolton and Roederer, 2009). 
 
2.5.2.1 Intracellular cytokine staining method 
Cell stimulation: After the isolation of mononuclear cells from blood or mucosal samples, 
the cells were stimulated with antigen.  For cell stimulation, cells were adjusted to the 
following concentrations: 
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 PBMCs: 5 million cells per ml 
 MMCs: Between 1.5 million and 2.5 million cells per ml depending on the number 
of cells available 
200µl of the cell suspension was then added to each of five wells and antigen added as 
appropriate.  The wells were: 
 Non-stimulated, non-stained 
 Non-stimulated, stained (NS) 
 SEB (added 1µl of 100µg/ml stock) 
 Flu (added 0.5µl of 0.225µg/ml stock) 
 Ty21a (added 1µl 0.0632µg/µl stock) 
The cells were incubated at 37˚C for two hours, after which time 1µl of brefeldin A was 
added to each well.  The cells were then incubated for a further 16 hours before they were 
harvested. 
 
Harvesting cells:  After 18 hours, the cells from each well in the plate were transferred to 
separate FACS (fluorescence activated cell sorting) tubes.  200µl of RPMI-1640 medium was 
added to each well on the plate and pipetted up and down to remove any remaining non-
adherent cells.  These cells were then transferred to the corresponding FACS tubes and the 
tubes were vortexed and spun (800g, 7 minutes, 4˚C).  The supernatant was poured off and 
the cells resuspended in 1ml PBS containing 1µl ViViD (violet fluorescent reactive dye).  This 
viability dye is taken up by dead cells and is used to exclude them from analysis (Mahnke 
and Roederer, 2007).  The tubes were vortexed and then incubated for 20 minutes at 4˚C in 
the dark.  After this time, 1ml cold PBS was added to each tube and the tubes were spun 
(800g, 7 minutes, 4˚C).   
 
Surface staining: The supernatant was poured off and the cells resuspended in a cocktail of 
surface staining antibodies.  A saturating amount of antibody was used: 
 CD3-APC - 10µl  
 CD4-APCH7 - 5µl 
 CD8-PECy7 - 1µl 
 CD14-Pacific Blue - 2µl 
 CD19-Pacific Blue - 2µl 
 PBS - 5µl 
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This cocktail was added to all tubes except the non-stimulated, non-stained tube.  30µl PBS 
was then added to the NS and SEB tubes.  The tubes were vortexed and 30µl of solution 
transferred from each of these tubes into new FACS tubes which contained 70µl PBS.  2µl 
of beta7-PeCy5 was then added to the four original tubes.  The two ‘new’ tubes did not 
contain any beta7 antibody.  It was important to have these ‘fluorescence minus one 
controls’ in order to be able to accurately place gates on the beta7 negative and positive 
populations; the separation between these populations is poor. 
 
 The cells were then incubated for 15 minutes at 4˚C in the dark.  After this time, the cells 
were washed with 1ml PBS and resuspended in 250µl Cytofix/Cytoperm to permeabilise 
the cells for intracellular staining.  They were then incubated for 20 minutes at 4˚C in the 
dark before being washed with 1ml Perm/Wash.   
 
Intracellular staining: The cells were then resuspended in a cocktail of intracellular 
cytokine staining antibodies.   A saturating amount of antibody was used: 
 IFNγ-AF700 - 1µl 
 TNFα – AF488 – 2.5µl 
 IL2-PE - 10µl 
 PermWash – 1.5µl 
Next, the cells were incubated for 30 minutes at 4˚C in the dark.  After this time, the cells 
were washed with 1ml PermWash and resuspended in 350µl FACS flow before acquisition.  
Acquisition was carried out on a BD LSR II flow cytometer (BD Biosciences UK) and analysis 
was performed using FlowJo (Tree Star Inc., San Carlos, CA). 
2.5.3 Lymphoproliferation assay 
This assay is also used for the detection of antigen-specific T cells.  Antigen-specific T cells 
must be able to proliferate rapidly in response to infection in order for the infection to be 
deal with effectively.  Cell proliferation can be measured using CFSE.  CFSE is a fluorescent 
dye which becomes incorporated in the cytoplasm of cells (Last'ovicka et al., 2009).  When 
the cells divide, CFSE is partitioned equally between the daughter cells and therefore 
diluted, allowing for the identification of up to ten discrete generations (Lyons, 2000).  This 
assay was only conducted using PBMCs; the number of MMCs collected was insufficient to 
run this assay in addition to the ICS assay. 
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2.5.3.1 Lymphoproliferation method 
Cell stimulation: After the isolation of PBMCs from blood, they were adjusted to a 
concentration of 1 million cells per ml.  The cells were then spun (800g, 7 minutes, 4˚C) and 
resuspended in 10ml PBS containing 1.25µM/ml of CellTraceTM CFSE.  The cells were 
incubated in the dark at 37˚C for 8 minutes, after which time 10ml PBS was added.  Next, 
the cells were spun (800g, 7 minutes, 4˚C) and resuspended in 5ml RPMI.  A cell count was 
conducted to make sure that the concentration of lymphocytes was between 0.8-1.2 
million cells per ml.  1ml of the cell suspension was then added to each of five wells and 
antigen added as appropriate.  The five wells were: 
 Non-stimulated, non-stained 
 Non-stimulated, stained 
 PHA (added 1µl of 0.5µg/ml stock) 
 Flu (added 2.5µl of 0.225µg/ml stock) 
 Ty21a (added 5µl of 0.0632µg/µl stock) 
The cells were incubated at 37˚C for seven days, after which time they were harvested. 
 
Harvesting cells:  After seven days, the cells from each well in the plate were transferred to 
separate FACS tubes.  1ml of RPMI was added to each well on the plate and pipetted up 
and down to remove any remaining non-adherent cells.  These cells were then transferred 
to the corresponding FACS tubes and the tubes were vortexed and spun (800g, 7 minutes, 
4˚C).  The supernatant was poured off and the cells resuspended in 1ml PBS.  The tubes 
were vortexed and then spun (800g, 7 minutes, 4˚C).   
 
Surface staining: The supernatant was poured off and the cells resuspended in a cocktail of 
surface staining antibodies.  A saturating amount of antibody was used: 
 CD3-APC - 10µl  
 CD4-APCH7 - 5µl 
 PBS - 5µl 
The cells were then incubated for 15 minutes at 4˚C in the dark.  After this time, the cells 
were washed with 0.5ml PBS and resuspended in 350µl FACS flow before acquisition.  
Acquisition was carried out on a BD LSR II flow cytometer and data analysis was performed 
using FlowJo. 
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2.6 REAGENTS 
Reagents from a number of manufacturers were used in this study (Table 2.1). 
Item Product number Manufacturer 
Lymphoprep 1114545 Axis-Shield 
Phosphate buffered saline 14190-169 Invitrogen 
RPMI-1640 R0883 Sigma-Aldrich 
L-glutamine G7513 Sigma-Aldrich 
Foetal bovine serum 10500-064 Invitrogen 
Tazocin - Wyeth Pharmaceuticals 
Amphotericin B  A2942 Sigma-Aldrich 
Collagenase II-S C1764 Sigma-Aldrich 
Blunt-end needles 130-091-558 Miltenyi Biotec 
Trypan Blue T8154 Sigma-Aldrich 
SEB S4881-1MG Sigma-Aldrich 
Influvac sub-unit - Solvay Biologicals B.V. 
Ty21a - Berna Biotech 
BD GolgiPlug
TM
 555029 BD Biosciences 
ViViD viability dye L34958 Invitrogen 
Anti-human CD3 APC 555342 BD Biosciences 
Anti-human CD4 APCH7 641398 BD Biosciences 
Anti-human CD8PECy7 557746 BD Biosciences 
Anti-human Beta7 PECy5 551059 BD Biosciences 
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Anti-human CD14 Pacific Blue 558121 BD Biosciences 
Anti-human CD19 Pacific Blue 560353 BD Biosciences 
BD Cytofix/Cytoperm
TM 
554722 BD Biosciences 
BD Perm/Wash 554723 BD Biosciences 
Anti-human IFN-γ AF700 557995 BD Biosciences 
Anti-human TNF-α AF488 557722 BD Biosciences 
Anti-human IL2 PE 559334 BD Biosciences 
BD FACSFlow
TM 
Sheath Fluid 342003 BD Biosciences 
Anti-mouse compensation particles set 552843 BD Biosciences 
Anti-rat compensation particles set 552844 BD Biosciences 
CFSE C34554 Invitrogen 
PHA L2769 Sigma-Aldrich 
Table 2.1 A list of the reagents used in this study along with product numbers and 
manufacturers. 
2.7 STATISTICAL ANALYSIS  
All graphs were made using GraphPad Prism 5 and show means and 95% confidence 
intervals.  Statistical analyses were performed using Stata version 11 and SPSS version 18.  
Statistical comparisons were computed using maximum likelihood generalised linear 
modeling (regression) methods, assuming a Normal distribution.  Because of the small 
sample size, bootstrapping was performed for each analysis, with 500 replicates per 
analysis, to provide more robust estimates of effect size (i.e. group/time differences).  
Comparisons were considered statistically significant if the bootstrapped confidence 
interval did not span zero.  Correlations were analysed using the Pearson product moment 
correlation. 
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CHAPTER 3: ANTIGEN-SPECIFIC CD4+ T-CELL IMMUNE 
RESPONSES IN PERIPHERAL BLOOD 
3.1 INTRODUCTION 
Typhoid bacilli enter the body in contaminated food or water.  They penetrate the gut 
mucosa and are ingested by macrophages, cells in which they are able to survive and 
multiply.  After 8-14 days, systemic infection with bacteraemia and fever is established 
(Gordon, 2008).  The nature of typhoid pathogenesis means that both humoral and cell-
mediated immune responses are important.  An antibody response is important in 
preventing mucosal invasion and protecting against bacteraemic organisms whereas a cell-
mediated response is essential for the elimination of intracellular bacilli (Ivanoff et al., 
1994).  Antigen-specific cell-mediated responses include the production and secretion of 
cytokines and the proliferation of antigen-specific clones.  Th1-type and pro-inflammatory 
cytokines such as IFNγ, IL-2, TNF-α and IL-6 are produced and secreted in response to 
immunisation with Ty21a (Pasetti et al., 2011). Cytokine production is a primary defence 
mechanism.  Cytokines have a number of functions, including the activation of 
macrophages, Th1/Th2 differentiation, T-cell proliferation, acute phase protein production 
and the promotion of inflammation (Murphy et al., 2008).  Lymphoproliferation, which is 
the ability of T cells to rapidly increase in number in response to infection, is a second 
important effector function of T cells.  Both cytokine production and lymphoproliferation 
can be measured in laboratory assays. 
3.2 RESEARCH QUESTIONS 
The importance of the cell-mediated immune response against S. Typhi suggests that its 
magnitude should be markedly greater in vaccinated individuals compared to unvaccinated 
individuals.  The testable questions were: 
1) Is there a difference in the percentage of typhoid antigen-specific cytokine-
producing CD4+ T cells in peripheral blood between unvaccinated and vaccinated 
individuals at day 0 (pre-vaccination) or day 18 (two weeks post-vaccination)?  
2) Is there a difference in the percentage of typhoid antigen-specific proliferating 
CD4+ T cells in peripheral blood between unvaccinated and vaccinated individuals 
at day 0 (pre-vaccination) or day 18 (two weeks post-vaccination)?  
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3.3 MATERIALS AND METHODS 
3.3.1 Study location and population 
As described in sections 2.1 and 2.2. 
3.3.2 Study design 
Venous blood (30-50ml) was collected from both groups on day 0 (pre-immunisation 
sample) and day 18 (post-immunisation sample collected two weeks after the last dose of 
the vaccine).  See section 2.3.1 for information about the vaccine and vaccination. 
3.3.3 Sample processing 
Peripheral blood was processed as described in section 2.4.1.1 and PBMCs were counted as 
described in section 2.4.2. 
3.4.4 Flow cytometry phenotyping assays 
3.4.4.1 Intracellular cytokine staining assay 
As described in section 2.5.2. 
The antigens used for stimulation are described in section 2.5.1. 
Analysis of the data was performed on FlowJo (Treestar Inc., San Carlos, CA) using the 
gating strategy shown in Figure 3.1. 
 
3.4.4.2 Lymphoproliferation assay 
As described in section 2.5.3. 
The antigens used for stimulation are described in section 2.5.1. 
Analysis of the data was performed on FlowJo (Treestar Inc., San Carlos, CA) using the 
gating strategy shown in Figure 3.2. 
3.4.5 Statistical analysis 
Statistical analyses were performed using Stata version 11 and SPSS version 18.  There were 
insufficient observations to make a definitive conclusion about the statistical distribution of 
the observations.  Data were therefore analysed using a generalised linear (ANOVA) model 
assuming a Normal distribution with bootstrapping in order to obtain more reliable 
estimates of group differences.  All graphs were produced using GraphPad Prism 5.
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Figure 3.1 Intracellular cytokine staining flow cytometry gating strategy for peripheral blood.  PBMCs were stained with monoclonal antibodies directed 
against CD3, CD4, CD8, IFN-γ, TNF-α, IL-2 and a combination (on the same colour) of CD14, CD19 and ViViD, a viability marker.  Single cells were identified 
using forward scatter properties and lymphocytes were then identified using forward scatter and side scatter.  The ‘dump’ channel was used to remove 
monocytes, B cells and dead lymphocytes.  CD4+ T cells were then positively identified by CD3 and CD4.  Within the CD4+ T cell population, cells producing 
IFN-γ, TNF-α or IL-2 were identified.  Combination gating was used to identify single-, double- and triple-producing cells. 
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Figure 3.2 Lymphoproliferation assay flow cytometry gating strategy for peripheral blood.  PBMCs were stained with monoclonal antibodies directed 
against CD3 and CD4.  Lymphocytes were identified using forward scatter and side scatter properties.  CD4+ T cells were then positively identified by CD3 
and CD4.  CD4 was then plotted against CFSE and proliferating CD4+ T cells were identified.  
40 
 
3.4 RESULTS 
3.4.1 Characteristics of the study population 
Study number Female (F) or male 
(M) 
Age Vaccine (V) or 
control (C) 
Assay 
1 F 44 V* ICS, CFSE 
2 M 44 V* - 
3 F 22 C ICS,CFSE 
4 F 27 C ICS, CFSE 
5 M 38 V ICS, CFSE 
6 M 26 V CFSE 
7 M 58 V ICS, CFSE 
8 F 21 V ICS, CFSE 
9 M 24 V* ICS 
10 F 22 C ICS 
11 M 25 V* ICS, CFSE 
12 M 23 C ICS, CFSE 
13 F 27 V ICS 
14 F 21 V* ICS 
15 F 26 C ICS, CFSE 
16 F 26 C ICS, CFSE 
17 M 22 C - 
Table 3.1 Demographic characteristics of the study population for peripheral blood 
assays.  * represents individuals who had received a parenteral typhoid vaccination, either 
whole cell or Vi polysaccharide, more than three years previously.  Individuals who had 
received a typhoid vaccine within the last three years were excluded from the study. 
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The ICS assay was performed on samples from eight vaccinated individuals (median age 26, 
age range 21-58, four females) and six control individuals (median age 24.5, age range 22-
27, five females).  The CFSE assay was performed on samples from six vaccinated 
individuals (median age 32, age range 21-58, two females) and five control individuals 
(median age 26, age range 22-27, four females). 
3.4.2 The proportion of CD4+ T cells is similar between control and 
vaccinated individuals at day 0 and day 18 
The percentage of viable lymphocytes that were CD4+ was calculated for both groups at 
both time points for the PBMCs used in the ICS assay (Figure 3.3) and the proliferation 
assay (Figure 3.4).  This was done in order to be confident that it was reasonable to then 
compare both the proportion of antigen-specific cytokine-producing CD4+ T cells and the 
proportion of antigen-specific proliferating CD4+ T cells between the two groups at the two 
time points.  The percentage of viable lymphocytes that were CD4+ was similar between all 
groups in both cases. 
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Figure 3.3 The percentage of viable lymphocytes in peripheral blood that express CD4 in 
the ICS assay.  Lines represent the mean and 95% confidence interval. 
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Figure 3.4 The percentage of viable lymphocytes in peripheral blood that express CD4 in 
the CFSE lymphoproliferation assay.  Lines represent the mean and 95% confidence 
interval. 
 
3.4.3 When cells are unstimulated, there is no statistically significant 
difference in the proportion of cytokine-producing CD4+ T cells between 
the control and vaccinated groups  
Cytokine production was measured in CD4+ T cells that had not been stimulated by antigen 
(Figure 3.5).  There was no statistically significant difference in the mean percentage of 
cytokine-producing CD4+ T cells between the control and vaccinated groups at day 0 
(0.103% vs. 0.091%, bootstrapped 95% CI of -0.022 to +0.046) or day 18 (0.117% vs. 
0.116%, bootstrapped 95% CI of -0.102 to +0.097).  Furthermore, there was no statistically 
significant difference between day 0 and day 18 for the control group (0.103% vs. 0.117%, 
bootstrapped 95% CI of -0.058 to +0.086) or the vaccinated group (0.091% vs. 0.116%, 
bootstrapped 95% CI of -0.017 to +0.067). 
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Figure 3.5 CD4+ T cell responses in unstimulated cells from peripheral blood.  The 
percentage of unstimulated CD4+ T cells producing cytokine in the control and vaccinated 
groups at day 0 and day 18.  Cytokine-producing cells are defined as those producing any 
combination of IFN-γ, TNF-α and IL-2.  Lines represent the mean and the 95% confidence 
interval. 
 
3.4.4 In vaccinated individuals, there is no statistically significant 
difference in the proportion of typhoid antigen-specific cytokine-
producing CD4+ T cells between day 0 and day 18 
To determine if there was evidence of a response to the oral typhoid vaccine Ty21a in 
peripheral blood, the magnitude of the CD4+ T cell response to Ty21a was measured by an 
ICS assay.  SEB and flu antigen were used as positive controls.  The magnitude of the 
response measured in unstimulated cells was subtracted from that measured in stimulated 
cells in order to make the response comparable between individuals.  A positive response 
was measured when cells were stimulated with SEB, flu and Ty21a; the response was above 
that measured in unstimulated cells.  Figure 3.6 shows representative flow cytometry dot 
plots from a vaccinated individual.   
SEB 
There was no statistically significant difference in the mean percentage of cytokine-
producing CD4+ T cells between the control and vaccinated groups at day 0 (7.333% vs. 
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6.311%, bootstrapped 95% CI of -1.281 to +3.326) or day 18 (4.697% vs. 10.729%, 
bootstrapped 95% CI of -20.764 to +3.605) when cells were stimulated with SEB.  There was 
a statistically significant difference between day 0 and day 18 for the control group (7.333% 
vs. 4.697%, bootstrapped 95% CI of -3.879 to -1.394) but not for the vaccinated group 
(6.311% vs. 10.729%, bootstrapped 95% CI of -3.788 to +12.623) (Figure 3.7A).   
 
Flu 
Similarly, there was no statistically significant difference in the mean percentage of 
cytokine-producing CD4+ T cells between the control and vaccinated groups at day 0 
(0.142% vs. 0.132%, bootstrapped 95% CI of -0.078 to +0.098) or day 18 (0.400% vs. 
0.150%, bootstrapped 95% CI of -0.269 to +0.822) when cells were stimulated with flu.  
Furthermore, there was no statistically significant difference between day 0 and day 18 for 
the control group (0.142% vs. 0.400%, bootstrapped 95% CI of -0.254 to +0.769) or the 
vaccinated group (0.132% vs. 0.150%, bootstrapped 95% CI of -0.022 to +0.057) (Figure 
3.7B).   
 
Ty21a 
When cells were stimulated with Ty21a, there was no statistically significant difference in 
the mean percentage of cytokine-producing CD4+ T cells between the control and 
vaccinated groups at day 0 (0.084% vs. 0.091%, bootstrapped 95% CI of -0.081 to +0.066) 
but there was a statistically significant difference between the two groups at day 18 
(0.030% vs. 0.124%, bootstrapped 95% CI of -0.149 to -0.028).  Unexpectedly, there was a 
statistically significant fall in the mean percentage of cytokine-producing CD4+ T cells in the 
control group between day 0 and day 18 (0.084% vs. 0.030%, bootstrapped 95% CI of -
0.092 to -0.016), and this contributed markedly to the overall difference between controls 
and vaccinated groups at day 18.  Although there was a rise in the mean percentage of 
cytokine-producing CD4+ T cells in the vaccinated group between day 0 and day 18, this 
rise was not statistically significant even after bootstrapping (0.091% vs. 0.124%, 
bootstrapped 95% CI of -0.005 to +0.070)(Figure 3.7C). 
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Figure 3.6 Representative flow cytometry dot plots from a vaccinated individual for the ICS assay.  PBMCs were stimulated with antigen and antigen-
specific CD4+ T cell responses were measured by intracellular cytokine staining.  The production of the cytokines IFN-γ, TNF-α and IL-2 was determined.  The 
antigens used for stimulation were influenza antigen, SEB and Ty21a, as described in section 2.5.1.
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Figure 3.7 Antigen-specific CD4+ T cell responses in peripheral blood as measured by an 
ICS assay.  A comparison of the percentage of CD4+ T cells producing cytokine in the 
control and vaccinated groups at day 0 (pre-vaccination) and day 18 (two weeks post-
vaccination) in response to stimulation with A) SEB, B) Flu and C) Ty21a.  Cytokine-
producing CD4+ T cells are defined as those producing any combination of IFN-γ, TNF-α and 
IL-2.  Red dots represent previously vaccinated individuals.  Lines represent the mean and 
the 95% confidence interval. 
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3.4.5 When cells are unstimulated, there is no statistically significant 
difference in the proportion of proliferating CD4+ T cells between the 
control and vaccinated groups  
Lymphoproliferation was measured in CD4+ T cells that had not been stimulated by antigen 
(Figure 3.8).  There was no statistically significant difference in the mean percentage of 
cytokine-producing CD4+ T cells between the control and vaccinated groups at day 0 
(0.904% vs. 0.916%, bootstrapped 95% CI of -1.375 to +1.351) or day 18 (2.221% vs. 
4.209%, bootstrapped 95% CI of -8.977 to +5.027).  There was a statistically significant 
difference between day 0 and day 18 for the control group (0.904% vs. 2.221%, 
bootstrapped 95% CI of +0.039 to +2.595) but not for the vaccinated group (0.916% vs. 
4.209%, bootstrapped 95% CI of -1.924 to +8.510). 
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Figure 3.8 CD4+ T cell responses in unstimulated cells from peripheral blood.  The 
percentage of unstimulated CD4+ T cells that proliferated in the control and vaccinated 
groups at day 0 and day 18.  Lines represent the mean and the 95% confidence interval. 
 
3.4.6 In vaccinated individuals, there is no statistically significant 
difference in the proportion of proliferating typhoid antigen-specific CD4+ 
T cells between day 0 and day 18 
Evidence of a response to Ty21a in peripheral blood was also assessed by investigating the 
proliferative capacity of CD4+ T cells after stimulation with Ty21a.  PHA and flu antigen 
were used as positive controls.  The magnitude of the response measured in unstimulated 
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cells was subtracted from that measured in stimulated cells in order to make the response 
comparable between individuals.  A positive response was measured when cells were 
stimulated with PHA, flu and Ty21a; the response was above that measured in 
unstimulated cells.  Figure 3.9 shows representative dot plots from a vaccinated individual. 
PHA 
There was no statistically significant difference in the mean percentage of proliferating 
CD4+ T cells between the control and vaccinated groups at day 0 (54.316% vs. 48.717%, 
bootstrapped 95% CI of -14.767 to +25.964) or day 18 (38.879% vs. 38.891%, bootstrapped 
95% CI of -21.362 to +23.859) when cells were stimulated with PHA.  There was a 
statistically significant difference between day 0 and day 18 for the control group (54.316% 
vs. 38.879%, bootstrapped 95% CI of -27.111 to -3.763) but not for the vaccinated group 
(48.717% vs. 38.391%, bootstrapped 95% CI of -33.903 to +13.250)(Figure 3.10A).   
 
Flu 
Similarly, there was no statistically significant difference in the mean percentage of 
proliferating CD4+ T cells between the control and vaccinated groups at day 0 (29.370% vs. 
14.211%, bootstrapped 95% CI of -6.872 to +37.189) or day 18 (23.779% vs. 21.474%, 
bootstrapped 95% CI of -24.711 to +39.161) when cells were stimulated with flu.  
Furthermore, there was no statistically significant difference between day 0 and day 18 for 
the control group (29.370% vs. 23.779%, bootstrapped 95% CI of -33.665 to +22.483) or the 
vaccinated group (14.211% vs. 21.474%, bootstrapped 95% CI of -12.931 to +27.457)(Figure 
3.10B).  
 
Ty21a  
When cells were stimulated with Ty21a, there was no statistically significant difference in 
the mean percentage of proliferating CD4+ T cells between the control and vaccinated 
groups at day 0 (3.972% vs. 2.092%, bootstrapped 95% CI of -1.300 to +5.060) or day 18 
(3.527% vs. 3.971%, bootstrapped 95% CI of -6.522 to +1.890).  Furthermore, there was no 
statistically significant difference between day 0 and day 18 for the control group (3.972% 
vs. 3.527%, bootstrapped 95% CI of -1.815 to +0.925) or the vaccinated group (2.092% vs. 
3.971%, bootstrapped 95% CI of -0.403 to +4.161)(Figure 3.10C). 
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Figure 3.9 Representative flow cytometry dot plots from a vaccinated individual for the lymphoproliferation assay.  PBMCs were stimulated 
with antigen and antigen-specific CD4+ T cell responses were measured using a lymphoproliferation assay.  The antigens used for stimulation were 
influenza antigen, PHA and Ty21a, as described in section 2.5.1.
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Figure 3.10 Antigen-specific proliferating CD4+ T cell responses in peripheral blood as 
measured by a lymphoproliferation assay.  A comparison of the percentage of 
proliferating CD4+ T cells in the control and vaccinated groups at day 0 (pre-vaccination) 
and day 18 (two weeks post-vaccination) in response to stimulation with A) PHA, B) flu and 
C) Ty21a.  Red dots represent previously vaccinated individuals.  Lines represent the mean 
and the 95% confidence interval. 
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3.4.7 Comparison of the cytokine-producing T cell profile in unvaccinated 
and vaccinated individuals at day 0 and day 18  
The cytokine-producing profile of unvaccinated (Figure 3.11A) and vaccinated (Figure 
3.11B) individuals at day 0 and day 18 was described by calculating the proportions of 
single-, double- and triple-producing CD4+ T cells (IFN-γ, TNF-α, IL-2, IFN-γ + TNF-α, IFN-γ + 
IL-2, IL-2 + TNF-α, IFN-γ + TNF-α + IL-2) in the total typhoid antigen-specific cytokine-
secreting CD4+ T cell population.  In both unvaccinated and vaccinated individuals single-, 
double- and triple-producing effector T cells are all present.  All three of the cytokines 
measured contribute to the antigen-specific CD4+ T cell cytokine response. 
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Figure 3.11A The proportions of single-, double- and triple- cytokine-producing typhoid antigen-specific CD4+ T cells in peripheral blood at day 0 and day 
18 in the control group.  Lines represent the mean and the 95% confidence interval. 
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Figure 3.11B The proportions of single-, double- and triple- cytokine-producing typhoid antigen-specific CD4+ T cells in peripheral blood at day 0 and day 
18 in the vaccinated group.  Lines represent the mean and the 95% confidence interval.
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3.5 DISCUSSION 
This study set out to determine whether there was evidence of a response to the live oral 
typhoid vaccine Ty21a in peripheral blood using two assays, an intracellular cytokine 
staining assay and a lymphoproliferation assay.  The ICS assay showed that when cells were 
stimulated with Ty21a, a statistically significant decrease in the mean percentage of 
typhoid antigen-specific cytokine-producing CD4+ T cells was observed in the control group 
between day 0 and day 18.  There was an increase in the mean percentage of typhoid 
antigen-specific cytokine-producing CD4+ T cells in the vaccinated group between the two 
time points but this increase was not statistically significant.  In the lymphoproliferation 
assay, an increase in the mean percentage of typhoid antigen-specific proliferating CD4+ T 
cells in the vaccinated group between day 0 and day 18 was observed, but this increase 
was not statistically significant.   
In the ICS assay, the proportion of viable CD4+ T cells in the control and vaccinated groups 
at day 0 and day 18 were similar.  This was also the case in the lymphoproliferation assay.  
In general, the proportion of viable CD4+ T cells was lower in the lymphoproliferation assay 
than the ICS assay.  The most likely explanation for this is that cells for use in the ICS assay 
are incubated overnight whereas those for use in the lymphoproliferation assay are 
incubated for a week.  After a week, the media in which the cells have been resting is likely 
to be nutrient scarce and unable to support all of the cells, resulting in cell death.  
When cytokine production was measured in unstimulated cells in the ICS assay, there was 
no statistically significant difference between the two groups at either time point or 
between the two time points for either group.  This was to be expected.  When cytokine 
production was measured in unstimulated cells in the lymphoproliferation assay, there was 
also no difference between the two groups at either time point or between the two time 
points in the vaccinated group.  There was a significant difference between the two time 
points in the control group.  With a larger sample size, it is likely that this difference would 
become non-significant. 
The production of cytokine-producing and proliferating CD4+ T cells in response to the 
positive controls is evidence that the cells that were isolated from peripheral blood were 
capable of responding to antigen stimulation.  For both assays, the mean percentage of 
antigen-specific cells in response to stimulation with the positive controls was expected to 
be similar between the two groups and the two time points; this was not the case.  For the 
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ICS assay, there was a statistically significant decrease in the mean percentage of antigen-
specific cells in the control group between day 0 and day 18 when cells were stimulated 
with SEB and for the lymphoproliferation assay, there was a statistically significant 
decrease in the control group between day 0 and day 18 when cells were stimulated with 
PHA.  These apparently anomalous results are most likely due to the relatively small sample 
size used. 
The statistically significant decrease in the mean percentage of typhoid antigen-specific 
cytokine-producing CD4+ T cells between day 0 and day 18 in the control group in the ICS 
assay was an unexpected result for which there is no obvious biological explanation.  Again, 
the most likely explanation for this result is that the sample size was very small (six 
individuals).  Two individuals had high values at day 0 – natural variation in the population 
is wide and there may also be random day-to-day variation in laboratory conditions.  It is 
possible that these two individuals had been exposed to Salmonella in the environment or 
that there was cross-reactivity with antigens from other bacteria (Lundgren et al., 2009), 
but this would not explain why the values had returned to ‘normal’ at day 18.  
The increase in typhoid antigen-specific cytokine-producing CD4+ T cells and proliferating 
CD4+ T cells after vaccination with Ty21a was not statistically significant but it was 
expected.  It is consistent with work carried out by others, in which vaccination with Ty21a 
induced systemic CD4+ T-helper type 1 responses and led to an increase in both the 
proliferation of and the IFN-γ production by blood T cells stimulated with the vaccine strain 
(Kilhamn et al., 2003; Lundin et al., 2002; Viret et al., 1999).  Studies in which individuals 
were orally vaccinated with other live attenuated S. Typhi strains, such as CVD 908-htrA 
and CVD 909 have also produced similar results (Tacket et al., 2000b; Wahid et al., 2007).  
Methodological differences between these studies and this current study may explain why 
statistical significance was not obtained in this study.  For example, cytokine release was 
measured with enzyme-linked immunosorbent assays as opposed to flow cytometry and 
proliferation was measured using 3[H]-thymidine incorporation as opposed to flow 
cytometry (Kilhamn et al., 2003; Lundin et al., 2002; Viret et al., 1999).   
There were also differences in the way in which Ty21a was prepared for cell stimulation.  In 
some studies it was formalin-inactivated (Viret et al., 1999) whilst in others it was heat-
killed in a water bath after subculture on horse blood agar plates (Kilhamn et al., 2003).  In 
this study, the vaccine was dissolved in PBS and then heat-killed at 95°C for thirty minutes.  
Other ways of preparing Ty21a include killing the bacteria using phenol and making a whole 
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cell solubilised preparation.  There is no consensus in the literature as to which is the best 
method of antigen preparation.  The concentration of S. Typhi used in this study may also 
have affected the results obtained.  However, the heat-killed Ty21a was titrated before use 
and higher concentrations than the one used in the assays were found to kill the majority 
of lymphocytes in lymphoproliferation assays.  Instead of using killed whole cell S. Typhi for 
stimulation, purified antigens such as flagella H-antigen or the Vi polysaccharide capsular 
antigen could be used.  However, the best protective correlate of any individual S. Typhi 
protein is unknown.  It would be inappropriate to use Vi antigen in this study because a 
polysaccharide antigen would not elicit antigen-specific cellular immune responses, and in 
any case, Ty21a does not possess the Vi antigen.   
Studies which were conducted using new generation vaccines such as CVD 909 are likely to 
have produced significant results because such vaccines are more immunogenic than 
Ty21a.  Additionally, these studies used autologous PBMCs, which had been stimulated 
with S. Typhi and grown to be APCs, to act as stimulator cells in the preparation of effector 
cells for use in an IFN-γ enzyme-linked immunosorbent spot assay (Wahid et al., 2007).  
This method was also used by a study in which volunteers were immunised with Ty21a 
(Salerno-Goncalves et al., 2002) and is likely to increase the magnitude of the resulting 
immune response.      
Other reasons why statistical significance may not have been achieved include the 
possibility that not all of the vaccinated individuals responded to the vaccine.  This is to be 
expected because the efficacy of the vaccine is not 100% (Black et al., 1990; Engels et al., 
1998).  In addition, due to a small sample size and natural variation in the population, the 
confidence intervals around the data are wide.  A larger sample size may resolve this issue.  
Including previously vaccinated individuals in the vaccinated group could have inflated the 
mean percentage of typhoid antigen-specific cytokine-producing CD4+ T cells at baseline 
because such individuals had some level of immunity to S. Typhi already.  When these 
individuals were re-vaccinated, the magnitude of the resultant immune response to S. 
Typhi compared to baseline would not have been as great as it would have been in naïve 
individuals.  Consequently, including these individuals in the vaccinated group may have 
decreased the mean percentage of typhoid antigen-specific cytokine-producing CD4+ T 
cells at day 18 compared to day 0.  This may help to explain why a significant result was not 
achieved in the ICS assay, but it is unlikely since most of the previously vaccinated 
individuals had the Vi polysaccharide vaccine (rather than the older whole-cell killed 
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typhoid vaccine), and Ty21a does not possess the Vi antigen.  The similarity at baseline 
between controls and vaccines also does not support this theory.  Previously vaccinated 
individuals did not appear to behave differently to naïve individuals in the 
lymphoproliferation assay. 
The cytokine-producing profiles of vaccinated and unvaccinated individuals show that 
single-, double- and triple- cytokine-producing T cells are present.  All three cytokines that 
were measured, IFN-γ, TNF-α and IL-2, contributed to the antigen-specific immune 
response.  Measuring three cytokines as opposed to one or two is preferable because it 
decreases the fraction of the antigen-specific population that is not picked up by the assay 
(Seder et al., 2008).  Whereas effector CD4+ T cells predominantly produce IFN-γ, Tcm 
produces IFN-γ, TNF-α and IL-2 and Tem produces mainly IFN-γ and TNF-α (Seder et al., 
2008; Woodland and Kohlmeier, 2009).  However, surface phenotyping to distinguish 
between these T cell types was not carried out in this assay so it is not known what 
proportion of each T cell type was present in the blood.  
The main limitation of this study was the small number of individuals from whom samples 
were collected.  Under the terms of the ethics approval for this study, there was a 
requirement for a pause in recruitment in order to conduct an interim analysis after the 
data from a small number of individuals had been analysed.  This study reports the results 
of this interim analysis.  More individuals need to be recruited to increase the sample size 
and this is currently being conducted after a minor amendment to the ethics form was 
approved.  
Another limitation concerns the batch of Ty21a that was used for vaccination and cell 
stimulation.  After all of the laboratory work was completed, a letter was received from the 
vaccine company, Crucell, stating that they were withdrawing the batch of the vaccine that 
had been used in this study because their stability monitoring had revealed a lower than 
expected potency value for that particular batch.  It is possible that this decrease in 
potency affected the results that were obtained.  However, the letter did state that the 
vaccine was still safe and potent – there was just a possibility that it would not remain 
potent over the full period of its shelf life.  As the vaccine expiry date was 04/11 and the lab 
work was conducted between 05/10 and 08/10, this may not have been an issue.  In 
addition, the relationship between potency as measured by Crucell and cytokine-
production as measured here by ICS is unknown.  Future work should compare the reduced 
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potency batch of the vaccine with another batch in a number of individuals to see if the 
magnitude of the cell-mediated immune response is altered.   
A third limitation of this work was that vaccinated individuals were not observed taking 
each dose of their vaccine under the study protocol.  However, a text was sent to all 
individuals on the relevant days to remind them to take each dose of the vaccine.  Many 
texted back to confirm that they had taken the vaccine and all gave verbal confirmation at 
their next visit to the hospital.  
3.6 CONCLUSION 
In conclusion, this study shows a trend towards increased antigen-specific CD4+ T cell 
immune responses in individuals after vaccination with the live oral typhoid vaccine Ty21a.  
This finding is consistent with other work in this field.
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CHAPTER 4: ANTIGEN-SPECIFIC CD4+ T-CELL IMMUNE 
RESPONSES IN MUCOSAL TISSUE 
4.1 INTRODUCTION 
S. Typhi is a human-specific pathogen that invades the body through M cells overlying 
Peyer’s patches in the small intestine and transport across M cells brings typhoid bacilli into 
contact with gut-associated lymphoid tissue(Parry et al., 2002).  After 8-14 days, systemic 
infection is established (Gordon, 2008).  Exposure to S. Typhi therefore induces both local 
mucosal and systemic immune responses.  The production of mucosal IgA responses after 
ingestion of attenuated S. Typhi  strains has been well documented (Nisini et al., 1993; 
Tacket et al., 1997) but very little information is known about cellular immune responses to 
attenuated S. Typhi strains in the gut mucosa.  This is likely to be due to the difficulties in 
obtaining intestinal biopsies from humans.  However, work carried out with S. 
Typhimurium in mice has shown the importance of cytokines such as IFN-γ and TNF-α in 
providing protection against this bacterium (Mastroeni et al., 1992; Ramarathinam et al., 
1991).  In humans, it is known that effector T cells that are activated in Peyer’s patches 
(secondary lymphoid organs) migrate preferentially to intestinal tissue and not to other 
peripheral sites such as the lung or the skin.  Gut-homing T cells express both the integrin 
α4β7 which binds to MAdCAM1 on the blood vessels of the intestine and other mucosal 
surfaces and the chemokine receptor CCR9 which interacts with CCL25, a gut-associated 
chemokine (Woodland and Kohlmeier, 2009). 
4.2 RESEARCH QUESTIONS  
The nature of typhoid pathogenesis means that the gut cell-mediated immune response is 
likely to play a key role in protecting the host against S. Typhi.  It is therefore important to 
characterise this response.  It is also important to identify any correlation between gut and 
systemic cell-mediated responses because peripheral blood is more accessible than 
mucosal tissue and can be used in studies to evaluate future vaccine candidates.  The 
testable questions were: 
1) Is there a difference in the percentage of typhoid antigen-specific cytokine-
producing CD4+ T cells in duodenal biopsies between unvaccinated and vaccinated 
individuals?  
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2) Is there a difference in the percentage of typhoid antigen-specific cytokine-
producing CD4+ T cells in colonic biopsies between unvaccinated and vaccinated 
individuals?  
3) Is there a correlation between the percentage of typhoid antigen-specific cytokine-
producing CD4+ T cells in the duodenum and the percentage in the colon? 
4) Is there a correlation between systemic and mucosal antigen-specific T cell 
responses – do vaccinated individuals with a high percentage of typhoid antigen-
specific cytokine-producing CD4+ T cells in blood also have a high percentage in the 
duodenum? 
5) Does the percentage of typhoid antigen-specific cytokine-producing CD4+ T cells 
that are beta7+ differ between duodenal biopsies and peripheral blood? 
 
4.3 MATERIALS AND METHODS 
4.3.1 Study location and population 
As described in sections 2.1 and 2.2. 
4.3.2 Study design 
Ten individuals were vaccinated on day 0.  See section 2.3.1 for information about the 
vaccine and vaccination.  D2-D3 duodenal pinch biopsies were collected on day 18 from 10 
vaccinees and seven controls.  Sigmoid colonic biopsies were collected on day 18 from 
seven vaccinees and four controls. 
4.3.3 Sample processing 
Duodenal and colonic biopsies were processed as described in section 2.4.1.2 and MMCs 
were counted as described in section 2.4.2. 
4.4.4 Flow cytometry phenotyping assays 
4.4.4.1 Intracellular cytokine staining assay 
As described in section 2.5.2. 
The antigens used for stimulation are described in section 2.5.1. 
Analysis of the data was performed on FlowJo (Treestar Inc., San Carlos, CA) using the 
gating strategy shown in Figure 4.1.  In order to determine the percentage of antigen-
specific cytokine-producing CD4+ T cells that were also beta7+, the gating strategy shown 
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in Figure 4.2 was employed for duodenum and that shown in Figure 4.3 employed for 
peripheral blood. 
 
Staining of duodenal and colonic tissue with the fluorochrome CD4-APC-Cy7 was 
unsuccessful.  There is no obvious biological explanation for why this would be the case.  
Consequently, CD4+ T cells could not be positively gated on.  CD8- T cells had to be gated 
on instead, on the assumption that the CD8- T cell population was the same as the CD4+ T 
cell population.  Work carried out in this laboratory, in which gut tissue was successfully 
stained with CD4-Pacific Blue supports this assumption.  The CD4+ T cell population was 
shown to be equivalent to the CD8- T cell population. 
4.4.5 Statistical analysis 
Statistical analyses were performed using Stata version 11 and SPSS version 18.  There were 
insufficient observations to make a definitive conclusion about the statistical distribution of 
the observations.  Data were therefore analysed using a generalised linear (ANOVA) model 
assuming a Normal distribution with bootstrapping in order to obtain more reliable 
estimates of group differences.  All graphs were produced using GraphPad Prism 5. 
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Figure 4.1 Intracellular cytokine staining flow cytometry gating strategy for mucosal samples.  MMCs were stained with monoclonal antibodies directed 
against CD3, CD4, CD8, IFN-γ, TNF-α, IL-2 and a combination (on the same colour) of CD14, CD19 and ViViD, a viability marker.  Single cells were identified 
using forward scatter properties and lymphocytes were then identified using forward scatter and side scatter.  The ‘dump’ channel was used to remove 
monocytes, B cells and dead lymphocytes.  CD4 staining was unsuccessful in mucosal samples so CD8 negative cells were gated on instead on the 
assumption that CD8 negative cells are CD4 positive.  Within the CD4+ T cell population, cells producing IFN-γ, TNF-α or IL-2 were identified.  Combination 
gating was used to identify single-, double- and triple-producing cells.    
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Figure 4.2 Intracellular cytokine staining flow cytometry gating strategy including beta7 for mucosal samples.  MMCs were stained with monoclonal 
antibodies directed against CD3, CD4, CD8, IFN-γ, TNF-α, IL-2 and a combination (on the same colour) of CD14, CD19 and ViViD, a viability marker.  Single 
cells were identified using forward scatter properties and lymphocytes were then identified using forward scatter and side scatter.  The ‘dump’ channel was 
used to remove monocytes, B cells and dead lymphocytes.  CD4 staining was unsuccessful in mucosal samples so CD8 negative cells were gated on instead 
on the assumption that CD8 negative cells are CD4 positive.  Within the CD4+ T cell population, beta7+ cells were identified.  This was done by gating on the 
beta 7 negative population in a tube of PBMCs to which all the fluorochromes except beta 7 had been added.  Within the CD4+ beta7+ population, cells 
producing IFN-γ, TNF-α or IL-2 were identified.  Combination gating was used to identify single-, double- and triple-producing cells.    
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Figure 4.3 Intracellular cytokine staining flow cytometry gating strategy including beta7 for peripheral blood.  PBMCs were stained with monoclonal 
antibodies directed against CD3, CD4, CD8, IFN-γ, TNF-α, IL-2 and a combination (on the same colour) of CD14, CD19 and ViViD, a viability marker.  Single 
cells were identified using forward scatter properties and lymphocytes were then identified using forward scatter and side scatter.  The ‘dump’ channel was 
used to remove monocytes, B cells and dead lymphocytes.  CD4+ T cells were then positively identified by CD3 and CD4.  Within the CD4+ T cell population, 
beta7+ cells were identified.  This was done by gating on the beta7 negative population in a tube of PBMCs to which all the fluorochromes except beta7 had 
been added.  Within the CD4+ beta7+ population, cells producing IFN-γ, TNF-α or IL-2 were identified.  Combination gating was used to identify single-, 
double- and triple-producing cells.    
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4.4 RESULTS 
4.4.1 Characteristics of the study population 
Study number Female (F) or male 
(M) 
Age Vaccine (V) or 
control (C) 
Assay 
1 F 44 V* - 
2 M 44 V* - 
3 F 22 C Duo + Colon ICS 
4 F 27 C Duo ICS 
5 M 38 V Duo + Colon ICS 
6 M 26 V - 
7 M 58 V - 
8 F 21 V Duo + Colon ICS 
9 M 24 V* Duo + Colon ICS 
10 F 22 C Duo + Colon ICS 
11 M 25 V* Duo + Colon ICS 
12 M 23 C Duo ICS 
13 F 27 V Duo ICS 
14 F 21 V* Duo + Colon ICS 
15 F 26 C Duo ICS 
16 F 26 C Duo + Colon ICS 
17 M 22 C Duo + Colon ICS 
Table 4.1 Demographic characteristics of the study population for mucosal assays.  * 
represents individuals who had received a parenteral typhoid vaccination, either whole cell 
or Vi polysaccharide, more than three years previously.  Individuals who had received a 
typhoid vaccine within the last three years were excluded from the study. 
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The duodenum ICS assay was performed on samples from six vaccinated individuals 
(median age 24.5, age range 21-38, three females) and seven control individuals (median 
age 23, age range 22-27, six females).  The colon ICS assay was performed on samples from 
five vaccinated individuals (median age 24, age range 21-38, two females) and four control 
individuals (median age 22, age range 22-26, three females). 
4.4.2 The proportion of CD4+ T cells is similar between controls and 
vaccinated individuals  
The percentage of viable lymphocytes that were CD4+ was calculated for the control and 
vaccinated group for the MMCs used in the duodenal ICS assay (Figure 4.4) and the colonic 
ICS assay (Figure 4.5).  This was done in order to be confident that it was reasonable to 
compare the proportion of antigen-specific cytokine-producing CD4+ T cells between the 
two groups.  For both duodenal and colonic tissue, the percentage of viable lymphocytes 
that were CD4+ was similar between the control and the vaccinated group. 
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Figure 4.4 The percentage of viable lymphocytes in duodenal tissue that express CD4.  
Lines represent the mean and 95% confidence interval. 
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Figure 4.5 The percentage of viable lymphocytes in colonic tissue that express CD4.  Lines 
represent the mean and 95% confidence interval. 
 
4.4.3 In duodenal biopsies, when cells are unstimulated, there is no 
statistically significant difference in the proportion of cytokine-producing 
CD4+ T cells between the control and vaccinated groups  
Cytokine production was measured in duodenal CD4+ T cells that had not been stimulated 
by antigen (Figure 4.6).  There was no statistically significant difference in the mean 
percentage of cytokine-producing CD4+ T cells between the control and vaccinated groups 
(0.584% vs. 0.356%, bootstrapped 95% CI of -0.318 to +0.773). 
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Figure 4.6 CD4+ T cell responses in unstimulated cells from the duodenum.  The 
percentage of unstimulated CD4+ T cells producing cytokine in the control and vaccinated 
groups.  Cytokine-producing cells are defined as those producing any combination of IFN-γ, 
TNF-α and IL-2.   Lines represent the mean and the 95% confidence interval. 
 
4.4.4 In duodenal biopsies, there is a higher proportion of typhoid 
antigen-specific cytokine-producing CD4+ T cells in the vaccinated group 
compared to the control group 
To determine if there was evidence of a response to the oral typhoid vaccine Ty21a in 
duodenal biopsies, the magnitude of the CD4+ T cell response to Ty21a was determined 
using an intracellular cytokine staining assay.  SEB and flu antigen were used as positive 
controls.  The magnitude of the response measured in unstimulated cells was subtracted 
from that measured in stimulated cells in order to make the response comparable between 
individuals.  A positive response was measured when cells were stimulated with SEB, flu 
and Ty21a; the response was above that measured in unstimulated cells.  Figure 4.7 shows 
representative flow cytometry dot plots from a vaccinated individual. 
There was no statistically significant difference in the mean percentage of cytokine-
producing CD4+ T cells between the control and vaccinated groups when cells were 
stimulated with SEB (30.128% vs. 30.648%, bootstrapped 95% CI of -6.204 to +5.163)(Figure 
4.8A).  However, when cells were stimulated with flu (Figure 4.8B), there was a statistically 
significant increase in the mean percentage of antigen-specific cytokine-producing CD4+ T 
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cells in the vaccinated group compared to the control group (6.197% vs. 1.891%, 
bootstrapped 95% CI of -7.822 to -0.730). 
When cells were stimulated with Ty21a (Figure 4.8C), there was a statistically significant 
increase in the mean percentage of typhoid antigen-specific cytokine-producing CD4+ T 
cells in the vaccinated group compared to the control group (1.041% vs. 0.604%, 
bootstrapped 95% CI of +0.005 to +0.807). 
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Figure 4.7 Representative flow cytometry dot plots from a vaccinated individual.  MMCs were stimulated with antigen and antigen-specific CD4+ T cell 
responses were measured by intracellular cytokine staining.  The production of the cytokines IFN-γ, TNF-α and IL-2 was determined.  The antigens used for 
stimulation were influenza antigen, SEB and Ty21a, as described in section 2.5.1. 
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Figure 4.8 Antigen-specific CD4+ T cell responses in the duodenum as measured by an ICS 
assay.  A comparison of the percentage of CD4+ T cells producing cytokine in the control 
and vaccinated groups in response to stimulation with A) SEB, B) Flu and C) Ty21a.  
Cytokine-producing CD4+ T cells are defined as those producing any combination of IFN-γ, 
TNF-α and IL-2.  Red dots represent previously vaccinated individuals.  Lines represent the 
mean and the 95% confidence interval. 
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4.4.5 In colonic biopsies, when cells are unstimulated, there is no 
statistically significant difference in the proportion of cytokine-producing 
CD4+ T cells between the control and vaccinated groups  
Cytokine production was measured in CD4+ T cells from the colon that had not been 
stimulated by antigen (Figure 4.9).  There was no statistically significant difference in the 
mean percentage of cytokine-producing CD4+ T cells between the control and vaccinated 
groups (6.657% vs. 1.729%, bootstrapped 95% CI of -1.141 to +11.298). 
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Figure 4.9 CD4+ T cell responses in unstimulated cells from the colon.  The percentage of 
unstimulated CD4+ T cells producing cytokine in the control and vaccinated groups.  
Cytokine-producing cells are defined as those producing any combination of IFN-γ, TNF-α 
and IL-2.   Lines represent the mean and the 95% confidence interval. 
 
4.4.6 In colonic biopsies, there is no difference in the proportion of 
antigen-specific cytokine-producing CD4+ T cells in the vaccinated group 
compared to the control group  
To determine if there was evidence of a response to the oral typhoid vaccine Ty21a in 
colonic biopsies, the magnitude of the CD4+ T cell response to Ty21a was determined using 
an intracellular cytokine staining assay.  SEB and flu antigen were used as positive controls.  
The magnitude of the response measured in unstimulated cells was subtracted from that 
measured in stimulated cells in order to make the response comparable between 
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individuals.  A positive response was measured when cells were stimulated with SEB, flu 
and Ty21a; the response was above that measured in unstimulated cells.  
There was no statistically significant difference in the mean percentage of cytokine-
producing CD4+ T cells between the control and vaccinated groups when cells were 
stimulated with SEB (21.959% vs. 19.037%, bootstrapped 95% CI of -4.107 to +9.952)(Figure 
4.10A) or flu (1.820% vs. 2.255%, bootstrapped 95% CI of -2.300 to +1.429)(Figure 4.10B). 
When cells were stimulated with Ty21a (Figure 4.10C), the difference in the mean 
percentage of antigen-specific cytokine-producing CD4+ T cells between the control group 
and the vaccinated group was not statistically significant (1.146% vs. 0.668%, bootstrapped 
95% CI of -1.909 to +0.850). 
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Figure 4.10 Antigen-specific CD4+ T cell responses in the colon as measured by an ICS 
assay.  A comparison of the percentage of CD4+ T cells producing cytokine in the control 
and vaccinated groups in response to stimulation with A) SEB, B) Flu and C) Ty21a.  
Cytokine-producing CD4+ T cells are defined as those producing any combination of IFN-γ, 
TNF-α and IL-2.  Red dots represent previously vaccinated individuals.  Lines represent the 
mean and the 95% confidence interval. 
75 
 
4.4.7 Comparison of cytokine-secreting T cell subsets in unvaccinated and 
vaccinated individuals at day 18 in peripheral blood and duodenum  
The cytokine-producing profile of unvaccinated (Figure 4.11A) and vaccinated (Figure 
4.11B) individuals at day 18 in peripheral blood and duodenum was described by 
calculating the proportions of single-, double- and triple-producing CD4+ T cells (IFN-γ, TNF-
α, IL-2, IFN-γ + TNF-α, IFN-γ + IL-2, IL-2 + TNF-α, IFN-γ + TNF-α + IL-2) in the total typhoid 
antigen-specific cytokine-secreting CD4+ T cell population.  In both blood and duodenum in 
unvaccinated and vaccinated individuals, single-, double- and triple-producing effector T 
cells are all present.  All three of the cytokines measured contribute to the antigen-specific 
CD4+ T cell cytokine response.  
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Figure 4.11A The proportions of single-, double- and triple- cytokine-producing typhoid antigen-specific CD4+ T cells in peripheral blood and duodenum 
in the control group.  Lines represent the mean and the 95% confidence interval. 
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Figure 4.11B The proportions of single-, double- and triple- cytokine-producing typhoid antigen-specific CD4+ T cells in peripheral blood and duodenum 
in the vaccinated group.  Lines represent the mean and the 95% confidence interval.
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4.4.8 The relationship between antigen-specific CD4+ T cell responses in 
duodenum and those in the colon is not strong 
In vaccinated individuals, there does not seem to be a strong correlation between the 
percentage of typhoid antigen-specific cytokine-producing cells in the duodenum and the 
percentage of typhoid antigen-specific cytokine-producing cells in the colon (Pearson 
correlation -0.621, p = 0.263)(Figure 4.12). 
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Figure 4.12 The relationship between the percentage of antigen-specific cytokine-
producing CD4+ T cells in duodenal tissue compared to colonic tissue in 
vaccinated individuals 
4.4.9 The relationship between antigen-specific CD4+ T cell responses in 
blood and those in duodenum is not strong 
In vaccinated individuals, there does not seem to be a strong correlation between the 
percentage of typhoid antigen-specific cytokine-producing cells in peripheral blood and the 
percentage of typhoid antigen-specific cytokine-producing cells in the duodenum (Pearson 
correlation +0.068, p = 0.899)(Figure 4.13). 
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Figure 4.13 The relationship between the percentage of antigen-specific cytokine-
producing CD4+ T cells in peripheral blood compared to duodenum in vaccinated 
individuals. 
4.4.10 The proportion of antigen-specific cytokine-producing CD4+ T cells 
that express beta7 differs between peripheral blood and duodenal 
biopsies   
The percentage of typhoid antigen-specific CD4+ T cells that expressed beta7 was 
significantly greater in duodenum than in blood (mean 75.05 vs. 51.92, bootstrapped 95% 
CI +7.72 to +37.97).  The percentage of antigen-specific CD4+ T cells expressing beta7 was 
also significantly greater in duodenum than in blood following stimulation with the two 
positive controls, SEB and flu (mean 23.02 vs. 73.37, bootstrapped 95% CI +43.71 vs. +56.65 
and mean 22.96 vs. 83.98, bootstrapped 95% CI +52.14 to +69.71, respectively)(Figure 
4.14). 
In blood, the percentage of typhoid antigen-specific CD4+ T cells that express beta7 was 
significantly greater than both the percentage of SEB antigen-specific CD4+ T cells (mean 
51.92 vs. 23.02, bootstrapped 95% CI +15.16 to +42.80) and the percentage of flu antigen-
specific CD4+ T cells (mean 51.92 vs. 22.96, bootstrapped 95% CI +14.58 to +45.19).  No 
significant difference was observed in this percentage between SEB and flu stimulation 
(mean 23.02 vs. 22.96, bootstrapped 95% CI -7.86 to +7.32)(Figure 4.14). 
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In duodenum, the percentage of flu antigen-specific CD4+ T cells that express beta7 was 
significantly greater than both the percentage of SEB antigen-specific CD4+ T cells (mean 
83.98 vs. 73.37, bootstrapped 95% CI -15.07 to -7.32) and the percentage of typhoid 
antigen-specific CD4+ T cells (mean 83.98 vs. 75.05, bootstrapped 95% CI -11.91 to -
6.17)(Figure 4.14). 
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Figure 4.14 A comparison of the percentage of cytokine-producing CD4+ T cells expressing 
beta7 in peripheral blood and duodenal biopsies.  Cytokine-producing cells are defined as 
those producing any combination of IFN-γ, TNF-α and IL-2.  Beta7 is a mucosal  homing 
marker.  Cells were stimulated separately with heat-killed Ty21a, flu and SEB (flu and SEB 
are both positive controls).  The graph includes participants in both the control and 
vaccinated groups as the key point is whether any antigen-specific cells express beta7, not 
whether vaccine-induced antigen-specific T cells express beta7.  Lines represent the mean 
and the 95% confidence interval. 
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4.5 DISCUSSION 
This study investigated whether there was evidence of an antigen-specific CD4+ T cell 
response to the licensed live oral typhoid vaccine Ty21a in mucosal tissue using an 
intracellular cytokine staining assay.  In duodenal tissue, there was no statistically 
significant difference in the mean percentage of antigen-specific cytokine-producing CD4+ 
T cells between the vaccinated and control group at baseline or when the cells were 
stimulated with SEB, but there was a statistically significant difference when the cells were 
stimulated with flu.  There was a statistically significant increase in the mean percentage of 
typhoid antigen-specific cytokine-producing CD4+ T cells in the vaccinated group compared 
to the control group.  In colonic tissue, there was no statistically significant difference in the 
mean percentage of antigen-specific cytokine-producing CD4+ T cells between the 
vaccinated and control group at baseline or when the cells were stimulated with SEB or flu, 
the positive controls.  There was also no difference in the mean percentage of typhoid 
antigen-specific cytokine-producing CD4+ T cells between the two groups.  In the 
vaccinated group, there was not a strong relationship between duodenum and colon or 
between blood and duodenum in terms of the percentage of typhoid antigen-specific 
cytokine-producing CD4+ T cells.  There was a statistically significant difference between 
blood and duodenum in the percentage of antigen-specific cytokine-producing CD4+ T cells 
that were beta7+, regardless of the antigen used for stimulation.  In addition, a significantly 
higher proportion of blood CD4+ T cells were beta 7+ when stimulated with typhoid as 
opposed to SEB or flu and a significantly higher proportion of duodenal CD4+ T cells were 
beta 7+ when stimulated with flu as opposed to SEB or typhoid.  
In the duodenum and colon ICS, the proportion of viable CD4+ T cells in the control group 
was similar to that in the vaccinated group, making it reasonable to then compare the 
antigen-specific CD4+ T cell responses between the two groups.  The production of antigen-
specific CD4+ T cell responses to the positive controls is evidence that the cells that were 
isolated from mucosal tissue were capable of responding to antigen stimulation.  The 
statistically significant increase in the mean percentage of antigen-specific CD4+ T cells in 
the duodenum in the vaccinated group compared to the control group when stimulated 
with flu was unexpected.  Possible explanations for this result include pure chance that 
more vaccinated individuals than control individuals had flu, but that this was not evident 
from the blood T cell responses.  This is the most likely explanation, and might not be seen 
with a larger sample size.  Alternatively, the vaccine may have led to non-specific 
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inflammation or priming of the gut, making cellular responses more likely in orally 
vaccinated individuals.  Finally, a non-specific or cross-reactive element in the vaccine may 
have caused an antigen-specific response to flu, although this seems unlikely. 
This study is the first in which duodenal and colonic biopsies were taken from individuals 
who were vaccinated with Ty21a to measure antigen-specific T cell responses.  Others have 
measured the antigen-specific T cell responses in PBMCs expressing gut homing markers 
and inferred that the response in these cells is representative of the response in the gut 
microenvironment.  For example, Wahid et al. found that immunisation with the oral 
attenuated CVD 909 typhoid vaccine elicited IFN-γ-secreting CD4+ memory T cells that 
were able to home to the gut (Wahid et al., 2008).  This result is consistent with the results 
from this study, in which vaccinated individuals showed an increased percentage of 
antigen-specific cytokine-producing CD4+ T cells compared to the controls.  In this study, 
vaccination had no effect on the cellular immune response in the colon.  This result would 
be expected if there is distinct compartmentalisation of the mucosal immune system.  If 
this was the case, the effector response would be stronger at the mucosal inductive site, 
i.e. the small intestine.  The lack of response in the colon may be explained by the fact that 
the duodenum and the colon are derived from embryologically distinct compartments.  The 
D3 segment of the duodenum from which biopsies were taken is derived from the 
embryological midgut and is supplied by the superior mesenteric artery, as is the terminal 
ileum.  The terminal ileum is the site where S. Typhi is internalised.  In contrast, the sigmoid 
colon (from which colonic biopsies were taken) is derived from the embryological hindgut 
which is supplied by the inferior mesenteric artery.   However, the lack of response may 
have been due to our small sample size and if the immune response was measured in a 
bigger number of individuals, an antigen-specific response may have been seen in the 
colon.   
Additionally, from looking at the literature, there is reason to believe that immunisation 
with oral vaccines could elicit effector responses at remote mucosal sites.  Studies in mouse 
models have shown that oral vaccination can elicit immune responses at remote mucosal 
sites (DiGiandomenico et al., 2004; Nayak et al., 1998).  DiGiandomenico et al. orally 
immunised mice with Salmonella Typhimurium expressing the antigen Pseudomonas 
aeruginosa O11 O antigen.  They found O11-specific IgA and IgG in bronchoalveolar lavage 
fluid and that the vaccine was efficacious against pneumonia caused by P. aeruginosa.  
There have also been a small number of trials of S. Typhi live vector constructs in humans.  
83 
 
A trial in which individuals were vaccinated with the S. Typhi vaccine strain CVD 908 
expressing the circumsporozoite protein of Plasmodium falciparum found that four out of 
seven individuals had a four-fold rise in jejunal secretory IgA antibodies against the 
circumsporzoite protein (Gonzalez et al., 1994).  In another study, individuals were 
vaccinated with the live attenuated S. Typhi strain CVD 908-htrA which expressed fragment 
C of tetanus toxin.   Systemic cellular immune responses were measured and 19 out of 20 
subjects showed proliferative responses to tetanus toxoid (Tacket et al., 2000a).  There is a 
need for trials in which mucosal cellular immune responses are measured in individuals 
who have been vaccinated with a S. Typhi vector vaccine. 
In vaccinated individuals, there was not a strong correlation between duodenum and colon 
cellular immune responses in terms of the percentage of antigen-specific cytokine-
producing CD4+ T cells in each.  There are a number of explanations for this result.  First, 
there may genuinely be no relationship between the duodenum and colon.  This may be 
because the duodenum and colon are derived from embryologically distinct compartments, 
as explained above.  Second, the relationship may have been obscured by commensal 
microorganisms which live in the colon.  These commensals may have led to a raised 
cellular immune response when cells were unstimulated, thereby blunting the response 
measured when cells were stimulated with Ty21a.  Third, the sample size may have been 
too small to detect a correlation. 
In vaccinated individuals, there was also no correlation between blood and duodenal 
immune responses with regard to the percentage of typhoid antigen-specific cytokine-
producing CD4+ T cells in each.  This may seem counter-intuitive; it would seem reasonable 
to think that if there was a high percentage of cytokine-producing T cells in blood, there 
would also be a high percentage in the duodenum.  However, the discrepancy between the 
responses in the two compartments may be a reflection of the fact that the mucosal 
immune system is distinct from the systemic immune system.  Alternatively, there may 
have been no significant correlation because the timing of the immune response in blood is 
different to that in mucosal tissue.  It would be expected that the immune response might 
take longer to develop in the blood compared to the duodenum.  Although the number of 
individuals in this study was small, this result is potentially important because it suggests 
that the immune response in the blood might not mirror the immune response in mucosal 
tissue.  This will have implications when it comes to using systemic immune responses in 
the evaluation of future oral typhoid vaccine candidates.  
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There was a statistically significant increase in the percentage of cytokine-producing CD4+ 
beta7+ T cells in the duodenum compared to that in peripheral blood.  A high percentage of 
beta7+ T cells would be expected in the duodenum because in order for T cells to home to 
mucosal surfaces such as the intestine, expression of the integrin α4β7 is required.  The 
ligand for this integrin, MAdCAM-1, is expressed by intestinal endothelial cells and 
intestinal lamina propria venules (Alford et al., 2008).  Homing is important in enabling 
effector T cells to enter non-lymphoid intestinal tissue (Johansson-Lindbom and Agace, 
2007).  In the peripheral blood, a certain proportion of antigen-specific T cells would be 
expected to express beta7 as these cells would have been activated in the gut and would 
be re-circulating back to the gut.  However, T cells activated in non-mucosal sites would not 
express beta7.  The proportion of antigen-specific T cells expressing beta7 in peripheral 
blood for non-mucosal pathogens would therefore be lower in blood than in the 
duodenum. 
A statistically significant increase was also observed in the percentage of cytokine-
producing CD4+ T cells that were beta7+ in blood when stimulated with typhoid as 
opposed to SEB or flu.  Typhoid is presented to the immune system through the 
gastrointestinal system whereas SEB is not; SEB is not biologically presented.  T cells against 
typhoid are activated in the gut and they then enter the circulation from where they home 
to the tissue in which they were originally primed due to the homing markers on their 
surface.  One would therefore expect to see a higher proportion of gut-homing T cells in 
the blood that were specific for typhoid and a lower proportion that were specific for SEB.  
The cytokine-producing profiles of T cells from the duodenum of vaccinated and 
unvaccinated individuals show that single-, double- and triple- cytokine-producing T cells 
are present.  All three cytokines that were measured, IFN-γ, TNF-α and IL-2, contributed to 
the antigen-specific immune response.  The cytokine-producing profiles of T cells from the 
duodenum and peripheral blood were broadly similar.  Surface phenotyping to distinguish 
between different T cell types was not carried out in this assay so the proportion of each T 
cell type present in duodenal tissue is not known.    
This study has limitations, a major one being the small number of individuals from whom 
data were collected and analysed.  There were not enough individuals in either the vaccine 
or control group to reach a definitive conclusion about the effect of the vaccine on mucosal 
immune responses.  However, as with the blood study, under the terms of the ethics 
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approval there was a requirement to conduct an interim analysis partway through the 
study.  More individuals need to be recruited to the study and this is currently taking place.   
A second limitation of this study was that staining of duodenal and colonic tissue with the 
fluorochrome CD4-APC-Cy7 was unsuccessful.  There is no obvious biological explanation 
for why this would be the case.  Consequently, CD4+ T cells could not be positively gated 
on.  CD8- T cells had to be gated on instead, on the assumption that the CD8- T cell 
population was the same as the CD4+ T cell population.  Work carried out in this lab, in 
which gut tissue was successfully stained with CD4-Pacific Blue supports this assumption.  
The CD4+ T cell population was shown to be equivalent to the CD8- T cell population.   
A further limitation of this study, as with the blood study, involves the low potency of the 
vaccine batch that was used for vaccination and cell stimulation.  Although the vaccine was 
still clinically potent, this may have influenced the results that were acquired. 
In the future, as with the blood study (chapter 3), more individuals need to be recruited to 
increase the sample size and the reduced potency batch of the vaccine should be compared 
with another batch of the vaccine.  Additionally, a fluorochrome other than CD4-APC-Cy7 
should be used in the flow panel so that positive gating can be used to identify CD4+ T cells.   
4.6 CONCLUSION 
In conclusion, this study shows an increase in the typhoid antigen-specific CD4+ T cell 
immune response in duodenal tissue after vaccination with Ty21a.  This result is consistent 
with the idea that local immune responses against pathogens that enter the body via a 
mucosal route are important.   However, it is unclear if this result was truly antigen-specific 
as there was also an increase in the antigen-specific CD4+ T cell response when cells were 
stimulated with flu.  The difference between the systemic and mucosal immune response 
to the vaccine suggests that only investigating peripheral immune responses to mucosal 
pathogens or vaccine candidates may not give a representative picture. 
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CHAPTER 5: FINAL DISCUSSION 
 
Mucosal surfaces are protected by a highly specialised mucosal immune system which is 
distinct from the systemic immune system.  Pathogens such as S. Typhi, which invade the 
body through the gut mucosa but can cause bacteraemia, should elicit both mucosal and 
systemic immune responses.  This study used two flow cytometric assays to measure 
mucosal and peripheral blood antigen-specific T cell responses in cells stimulated with 
heat-killed Ty21a in vaccinated and unvaccinated individuals.  
Firstly, antigen-specific cellular immune responses against Ty21a were measured in 
peripheral blood.  There was no statistically significant increase in the mean percentage of 
cytokine-producing or proliferating antigen-specific T cells in vaccinated individuals 
between day 0 and day 18.  Secondly, antigen-specific immune responses against Ty21a 
were measured in T lymphocytes from two mucosal tissues, duodenum and colon.  There 
was a statistically significant increase in the mean percentage of cytokine-producing T cells 
in vaccinated individuals compared to unvaccinated individuals in the duodenum but not in 
the colon.  However, a statistically significant difference between the two groups was also 
observed in the duodenum in response to stimulation with flu, making it unclear whether 
the response measured after stimulation with Ty21a was actually antigen-specific.  Thirdly, 
the correlation between the percentage of typhoid antigen-specific cytokine-producing T 
cells in duodenum and that in colon was investigated, as was the correlation between 
duodenum and blood.  Neither correlation was strong.  Lastly, the percentage of antigen-
specific cytokine-producing CD4+ T cells that were beta7+ was measured in the duodenum 
and in peripheral blood.  There was a statistically significant difference between the two 
samples regardless of the antigen with which cells were stimulated. 
Although statistical significance was not reached, there was a trend towards increased 
antigen-specific cytokine production and lymphoproliferation in vaccinated individuals 
compared to controls in blood, which is consistent with other studies.  With regard to 
mucosal tissue, this was the first time that duodenal and colonic biopsies have been used 
to assess cellular immune responses against Ty21a.  Previously, duodenal cellular responses 
have been estimated by using PBMCs expressing the mucosal homing marker beta7.  
Furthermore, such studies did not use Ty21a, but new generation unlicensed live oral 
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vaccines.  In this study, more T cells from the duodenum expressed beta 7 than T cells from 
peripheral blood, a finding that is also consistent with previous work. 
The results from this study support the theory that local cellular immune responses against 
pathogens such as S. Typhi, which are presented across mucosal membranes, are 
important.  This finding, coupled with the finding that the correlation between peripheral 
blood and mucosal cellular immune responses is not strong, highlights the need to identify 
correlates of protection in peripheral blood that reflect what is happening at the mucosal 
surface.  This is necessary for the accurate evaluation of future vaccine candidates against 
mucosal pathogens.   
The main limitation of this study is the small sample size.  Under the terms of the ethics 
approval, there was a requirement to conduct an interim analysis after a small number of 
individuals had been recruited.  This study reports the results of this interim analysis.  More 
individuals are currently being recruited to increase the sample size. 
Work currently being carried out includes recruiting more individuals to increase sample 
size and using frozen serum samples collected from individuals who were recruited to the 
study to look for humoral responses to the vaccine.  Correlations between humoral and 
cellular responses are also being investigated.  
Future work should involve measuring cellular immune responses at mucosal sites such as 
the lung because mouse models of S. Typhimurium vector vaccines containing respiratory 
antigens have provided protection against challenge by respiratory pathogens such as 
Streptococcus pneumoniae.  Such work would inform the development of S. Typhi vector 
vaccines against respiratory pathogens for use in humans.  Mucosal cellular immune 
responses should be measured against unlicensed new generation oral vaccines such as 
M01ZH09 and CVD 909 because these vaccines are more immunogenic than Ty21a. 
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Appendix 2 
Volunteers required  
The development of non-injected 
vaccines requires a good 
understanding of the immune 
responses produced as a result of 
oral vaccination.  
Healthy, non smoking volunteers are invited to participate 
in research investigating immune responses to a licensed, 
oral (by mouth) typhoid vaccine.  It does not matter if you 
have previously received a typhoid vaccine.  Participation will 
be as an outpatient and will include blood tests and one or 
two endoscopic (camera) procedures (gastroscopy and 
sigmoidoscopy or bronchoscopy) over the course of four 
weeks. 
 Remuneration will be paid for your time 
and inconvenience 
Please contact Dr. Sherouk El Batrawy, Sr. Lorna Roche or Dr. 
Stephen Gordon for further information on: 
0151 706 4863 or 0151 705 3172 
(or email lorna.roche@rlbuht.nhs.uk) 
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